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 Cell therapy is an emerging field in regenerative medicine that uses living cells to 
treat disease. The potential therapeutic benefit of cell therapy is creating a rapidly growing 
industry estimated to be a $55 billion global market by 2024. However, meeting this 
massive demand requires the development of novel tools and technology to solve the 
unique challenges facing the manufacturing of cell therapy. Compared with traditional 
biopharmaceutical manufacturing, cell therapy product manufacturing is considerably 
more challenging due to the greater complexity of working with living cell products. As a 
result, the cost of cell therapies remains unattainable for most patients, with a long lead 
time and low production capacity.  
 This Ph.D. thesis will describe the development and application of an agent-based 
simulation platform that can create digital representations of a single or multi-network of 
manufacturing facilities throughout a large region. The platform incorporates a customized 
manufacturing process for autologous products that are customized per patient, as well as 
a batch manufacturing process for allogeneic products. A set of case studies will be 
presented in the thesis to demonstrate how the platform enables manufacturers to devise 
system-level decisions to improve facility design, plan “what if” scenarios for unexpected 
disruptions, and address an unmet need for reducing costs, increasing speed, and improving 
yields for cell therapy production and distribution.  
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CHAPTER 1    INTRODUCTION 
 
1.1 Background 
Cell therapy is an emerging therapeutic method that uses a patient’s own cellular 
material to treat disease. Cell therapy has received regulatory approval for a small number 
of blood cancers (June, O’Connor, Kawalekar, Ghassemi, & Milone, 2018; Rosenberg & 
Restifo, 2015), and shown promising results in clinical trials for a number of other 
indications including blood disorders (Ribeil et al., 2017; Thompson et al., 2018), and 
autoimmune diseases (Ellebrecht et al., 2016; Miyara, Ito, & Sakaguchi, 2014). The 
transition from clinical trials to commercial products is evolving rapidly because of its 
tremendous potential benefits for patients. There are currently 1,085 companies developing 
cell therapies worldwide, with a total of 1,220 clinical trials as of the end of 2020 (Lambert, 
2021).   
Based on the origin of the cellular material, cell therapy can be categorized into 
autologous cell therapy (AuCT), where the patient’s own cells are used, or allogeneic cell 
therapy (AlCT), where the cellular material comes from a healthy donor. The use of 
autologous cells can significantly reduce the risk of immune rejection and disease 
transmission (Kazmi, Inglefield, & Lewis, 2009), but at the cost of increasing the 
complexity of the manufacturing and supply chain process. As the AuCT product is patient-
specific, a separate batch of cells is manufactured for each patient.  A typical manufacturing 
process for AuCT starts by taking a cell sample from the patient in the clinic, then 
transporting these cells to a central manufacturing facility for manipulation. At the 
manufacturing facility, these cells undergo isolation, purification, expansion, harvest, and 
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formulation. For a genetically modified cell product such as chimeric antigen receptor t-
cells (CAR T-Cell), the cells will also undergo activation and gene delivery through viral 
transduction or electroporation before expansion. After formulation, these cells are tested 
and then released back to the clinic for administration to the same donor patient (Bartel, 
2015; Levine, Miskin, Wonnacott, & Keir, 2017). 
Unlike the scalable allogeneic therapies, which can be modeled after therapeutic 
monoclonal antibodies (mAbs) production with established business models and robust 
supply chains, ideal manufacturing and distribution approaches have not yet been fully 
determined for AuCT. Many current manufacturing facilities for autologous therapies are 
designed or tuned to deliver innovative products that will be used in carefully controlled 
clinical trials. Notably, the facilities that are affiliated with universities or research centers 
usually have responsibilities other than manufacturing autologous therapies. For example, 
it is quite common that a production facility of an academic medical center supports several 
different clinical trials, including investigator-initiated trials. These “academic production 
facilities” (APFs) have the flexibility to reconfigure manufacturing space to produce 
different types of cell products. However, a significant challenge is responding to changes 
with real-time information in industrial production scenarios. Everything in every process, 
including machine schedules, personnel allocations, and reagent usage, is scheduled 
significantly before the actual production starts. Pre-deployment planning is a strategy that 
helps accomplish multiple types of tasks on time, rather than an efficient, low-cost, 
consistent strategy for accomplishing the same type of task. Considering that AuCT is an 
entirely patient-specific product, and the patient's condition is likely to change at any time, 
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this strategy, which relies on pre-planned production and distribution, is even less flexible 
in an industry setting. 
The few companies that so far produce FDA-approved commercial AuCT products, 
such as Novartis Pharmaceuticals Corporation, Gilead Sciences, and Dendreon, utilize 
their own dedicated manufacturing facilities. Unlike APFs, where different types of 
products keep the production process open for adjustment at any time, these “industrial 
production facilities” (IPFs) need to optimize the production process for a single or several 
similar products. At a much larger manufacturing scale, IPFs also need to develop a 
sophisticated supply chain network that can ensure reliable and on-time deliveries to 
treatment facilities across the country or the globe. In addition, the difficulty of many 
operational aspects in AuCT production facilities drastically increases with scaling up, 
such as production scheduling, prioritization, inventory management, and workforce 
management.  
Many unique challenges exist in scaling up AuCT manufacturing as illustrated in 
Table 1.1. At present, there are not many IPFs for AuCT, and there is thus still much room 
for exploration on the optimal configuration strategy. This thesis proposes the development 
of a simulation platform to model cell therapy manufacturing and supply chain to 
experiment with new configurations to help tackle these challenges. 
1.2 Challenges in autologous cell therapy manufacturing 
The AuCT supply chain network is composed of manufacturing facilities, suppliers, 
clinics, transport of specimens from clinics to facilities, and transport of therapies from 
facilities to clinics.  Each facility is comprised of bioreactors (the manufacturing capacity), 
AuCT orders assigned to the facility, reagent and supply inventory, and the skilled 
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workforce.  Scheduling and coordinating patients with spare production capacity at the 
manufacturing facility within the product shelf life can significantly increase the 
complexity for scaling out commercial production. As the production ramps up to meet 
national or even global demand, manufacturers must choose between a centralized or more 
decentralized manufacturing network to determine the optimal number and locations of the 
manufacturing facilities, as well as the functions and operations conducted at each facility 
(Harrison, Rafiq, & Medcalf, 2018). A simulation platform could be a valuable support 
tool to understand how these decisions will affect the manufacturing capacity, which in 
turn affects the cost of these cell products. In addition, a simulation platform could be used 
to study how delays affect the quality of the cells and optimize the scheduling of these 
manufacturing and quality testing steps. 
There is a need for real-time and efficient communication between clinics, 
manufacturers, and reagent suppliers. Real-time interaction between the manufacturing 
facility and the healthcare staff will allow better prediction of product delivery date based 
on the current manufacturing capacity. For example, if a patient's condition suddenly 
becomes unsuitable for AuCT, the clinic should immediately notify the manufacturer to 
cancel subsequent production to reduce the loss in terms of cost and manufacturing 
capacity, and the cancellation of this order may also result in subsequent changes in reagent 
requirements. Similarly, if the reagent supplier foresees a disruption, the manufacturer 
should be notified immediately to take appropriate action, which in turn will cause the 
clinic to adjust the patient's AuCT injection schedule. The complexity of interaction 
between parties in the AuCT supply chain network exceeds the interactions in supply chain 
networks of other existing industries. While no analytic tool is available to address the 
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complexity at this high level, it is feasible to capture this complex interaction using a 
multiscale simulation with built-in stochastic algorithms. 
Currently, the critical reagents in the manufacturing process of AuCT rely on only 
a few or, in many cases, the high-risk situation of a single supplier. Other high-risk 
situations include a reagent supply disruption, which could result in reagent shortages or 
stock-outs in all IPFs, significantly reducing yield and hence significantly reducing patient 
benefit. A simulation platform could assist in the evaluation of “what if” scenarios and the 
preparation of risk mitigation strategies. The efficiency and cost of deploying any risk 
mitigation strategy can also be estimated by running computational experiments on the 
supply chain simulation.    
According to the Regenerative Medicine Standards Landscape, there are over 60 
existing standards that are relevant for the cell therapy process (Nexight Group & Standards 
Coordinating Body, 2018). However, many of these relevant standards lack a sufficiently 
specific or useful guide for AuCT commercial development. The lack of standards can 
create significant difficulties in converting the clinical trial manufacturing process into a 
full-scale commercial manufacturing process (National Academies, 2017). A simulation 
platform for planning AuCT production will need to be flexible and have a high degree of 
freedom to allow the manufacturer to explore the impact of different standards on their 
manufacturing process. Such platform can support a policymaker with information 





Table 1.1 A list of challenges that differentiate AuCT manufacturing from conventional 
manufacturing problems 
Unique Challenges in Scaling AuCT Manufacturing 
• Time-dependent product quality that is hard to predict 
• Large patient-to-patient variability in the starting material that propagates to the 
final cell product 
• Lack of standards and industrial understanding to choose appropriate reagents, 
materials, and equipment for large scale commercial manufacturing that is 
FDA-compliant 
• Rapidly changing patient condition and disease progression 
• A complex logistic network that extends beyond manufacturing facilities 
• Vulnerable to supply disruption due to single sourcing for most materials 
 
 
1.3 Emerging allogeneic cell therapy manufacturing 
 Unlike the autologous approach, an allogeneic process does not require the 
collection of specimens from the patient receiving the therapy. This difference affects 
inbound logistics, manufacturing, and distribution in important ways. The raw material 
collection and manufacturing processes are decoupled from one another, as are the 
manufacturing and drug product distribution processes. The former processes are separated 
by a buffering step – all outputs of the manufacturing process are cryopreserved for 
inventory, with fulfillment originating from said inventory as needed.  
 As starting materials are donor- rather than patient-derived, manufacturing is not 
initiated by real-time requests, with apheresis conducted in line with availability at a 
manufacturing site. Products are manufactured in campaigns, which are planned to meet 
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the demand for stock and demand fulfillment. Resources can be procured and staged to 
meet the needs of the specific campaign, therefore leading to a less time-dependent 
scheduling process than is common in the production of autologous therapies. In this way, 
AlloCT resembles conventional small molecule or biologics supply chains.  
 While both autologous and allogeneic processes share most of the same unit 
operations and thereby present a similar degree of complexity, allogeneic production 
allows for production campaigns of lot size that spread time and cost across hundreds of 
doses. Furthermore, the ability to manufacture on the basis of donor material – with healthy 
donors being selected, screened, and subjected to extensive testing – and then to 
cryopreserve doses, enables a more comprehensive approach to quality control and a more 
timely delivery, as the leukapheresis and outbound logistics are eliminated as gating steps 
in the process.  
 Indeed, the ability to decouple the cell therapy from the patient has become a new 
frontier in this rapidly evolving space. Moreover, while questions remain regarding the 
therapeutic equivalency between autologous and allogeneic products, the need to reduce 
costs and increase economies of scale through standardization and process automation will 
continue to drive efforts to create effective allogeneic therapies. Some therapeutic 
candidates have begun to generate positive clinical results (Mailankody et al., 2020; 
Sommer et al., 2019), with more anticipated in the near future.  
 The transition to an allogeneic approach to CAR-T will certainly depend on 
therapeutic efficacy. However, it will also depend on cost. To date, efforts to map the costs 
associated with manufacturing and delivering CAR-T therapies have been limited, 
especially emerging allogeneic therapies. 
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1.4 Existing studies on cell therapy modeling 
Currently, there exist a few studies on analytic or empirical modeling for the cost 
of cell therapy manufacturing (Abou-El-Enein et al., 2013; Harrison, Rafiq, et al., 2018; 
Harrison, Zylberberg, Ellison, & Levine, 2019; M. J. Jenkins & Farid, 2018; Lopes, 
Sinclair, & Frohlich, 2018; McCollister et al., 2018; Simaria et al., 2013). Although these 
studies provide valuable information regarding the economics of the cell manufacturing 
process, none of them provide the information detailed enough to address issues specific 
to a single cell therapy facility, let alone the interactions between multiple facilities and 
different stakeholders. A simulation-based tool may serve better than oversimplified 
models in most decision-making scenarios. However, no such simulation tool can be found 
in the current body of literature. As a result, the development of a three-level (clinics, 
manufacturing facilities, and suppliers), two-scale (facility and supply chain network), 
stochastic simulation model is described in this thesis. This model may be used as a 
decision support system (DSS) for the cell therapy supply chain in service to manufacturers, 
health care providers, and ultimately patients. 
1.5 Aims and organization of the thesis 
 This thesis will describe a simulation-based decision support platform to help cell 
therapy manufacturers improve production and distribution by reducing lead time, failure 
rate, and production costs. The simulations help manufacturers identify problems early on 
and throughout the overall manufacturing and supply chain, and could lead to reduced costs, 
improved yield, quality, and speed for the regenerative medicine products. Simulation case 
studies for different cell types (CAR-T, MSC, and iPSC) and cell sources (autologous and 
allogeneic) are developed to test the validity of the platform. Case studies that inform 
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decision-making in cost reduction, automation, logistics, inventory management, risk 




Figure 1.1 Functional modules of the simulation-based decision support platform 
 
 The thesis is organized as follows: Chapter 2 describes the development and 
features of an agent-based simulation platform for autologous cell therapy manufacturing 
using the production of autologous CAR-T for cancer treatment as a case study. The 
chapter also describes how the platform can be used to identify bottlenecks in production 
and design computational experiments to improve the process to reduce cost and lead time. 
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 Chapter 3 describes the development of a decisional support tool for cost-effective 
bioprocess design for cell therapy. The chapter will establish a framework for conducting 
cost analysis for the cell therapy industry, investigate the cost structure of current products 
and potential areas for cost reduction, as well as provide a detailed case study on a cost-
effective design of an allogeneic mesenchymal stem cell (MSC) manufacturing facility for 
joint cartilage damage. 
 Chapter 4 provides a detailed case study describing how the decisional support 
tool can be used to produce a cost-effective design of a commercial manufacturing facility 
for the production of a cell therapy product containing human mesenchymal stem cells 
(MSCs) for the treatment of joint cartilage defects. 
 Chapter 5 investigates the impact of supply chain and labor disruption on cell 
therapy manufacturing performance and evaluates alternative scheduling policies to 
improve patient outcomes using the developed simulation platform. The platform will 
simulate different disruption and shortages scenarios during the COVID-19 pandemic 
(Fauci, Lane, & Redfield, 2020) and provide decision support on how manufacturers can 
build resilience to mitigate the impact of disruptions. 
 Chapter 5 summarizes the conclusions from this thesis and discusses some 
ongoing and future works to improve the decision support system and extend the 
application of the system to new possible avenues.  
 Some results presented in the thesis have already been published and presented in 
academic journals and conferences. Parts of the thesis are adapted from manuscripts that 
are published, submitted, or in preparation (Liu, Tseng, & Lin, 2019; Liu et al., 2021; Wang 




CHAPTER 2    AGENT-BASED SIMULATION MODEL FOR CELL 
THERAPY MANUFACTURING AND SUPPLY CHAIN 
 
2.1 Digital simulation framework for autologous cell therapy manufacturing 
The proposed simulation framework has an array of key features to address the 
unique challenges expounded in Chapter 1. These features include a multiscale structure, 
multiple key performance indicators (KPIs), stochasticity when appropriate, and a highly 
customizable framework. These features reflect the very minimal requirements to be able 
to capture the complexity of the AuCT supply chain problem. Sophisticated functions can 
be built upon the basic framework to solve specific cases. The design of the computational 
experiment depends on the specific users’ considerations of pinch points in sourcing, 
production, and delivery.  
2.1.1 Multiscale structure 
The most fundamental difference between the AuCT supply chain problem and 
conventional supply chain problems is that the AuCT supply chain model must include 
both the “microscale” activities inside a cell manufacturing facility and the “macroscale” 
interactions at the supply chain network level. In a conventional supply chain problem, the 
manufacturing facility and the supply chain network can be modeled separately since the 
products produced in the manufacturing facilities are interchangeable. Therefore, the 
manufacturing nodes in a conventional supply chain network model can be treated as 
“black boxes” where the detailed manufacturing procedures can be modeled with a 
separated simulation. However, in the AuCT supply chain problem, each product is linked 
with an individual patient. It is a truly build-to-order (BTO) supply chain for a bespoke 
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product. The patient's condition can influence the timing of production and quality control 
procedures. Moreover, the patient is not only the consumer of the product but also the 
supplier of the raw material. If the manufacturing process of any product fails due to any 
reason, a request for a new specimen may be issued from the manufacturing facility to the 
clinic. Therefore, in a simulation run, it is essential to ensure real-time communication 
between the manufacturing facility level and the supply chain level, which requires the 
model to contain both the micro and the macro scales. 
2.1.2 Microscale simulation 
The microscale simulation reflects any activities inside a manufacturing facility. 
The primary subsystems in a cell manufacturing facility include manufacturing procedures 
(Figure 2.1a), quality control procedures, inventory management, and resource 
management. Figure 2.1b shows the interface of the microscale simulation platform. The 
specimens from clinics arrive at the top-left corner and go through the acceptance check 
and the upstream processing. Then the specimens enter a queue, waiting for bioreactors, 
operators, and reagents to be assigned by the resource management subsystem. After the 
necessary resources are allocated, the specimens come to the expansion stage, where 
several quality control tests will be performed at different time points over the entire course. 
After the expansion, the products go through the downstream processing and release check 
subsequently. Qualified products are packed and distributed to the clinics for 
administration, which can be the same or different clinics from the ones where the 
specimens were collected. If the product fails any of the acceptance check, quality control 
tests, or the release check, the facility may request a new specimen to be sent from the 
patient. If the patient becomes unsuitable for treatment, a signal will be triggered and 
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abort/pause the corresponding manufacturing process. The inventory management 






Figure 2.1 The flow chart of activities inside a typical AuCT manufacturing facility; (b) 








Many communication ports exist at various components in this facility to ensure 
timely interactions with events at the macroscale level. The primary inlet port is at the 
arrival dock, where the requests and specimens sent from clinic nodes are accepted. The 
primary outlet port is at the pack and distribution dock, where the products are sent back 
to the requesting clinics. Every specimen in the facility also has a categorical variable, 
“Patient Status,” that links to the status of the patient. The framework handles a variety of 
specimens with patient categories using different actions regarding their manufacturing 
process. The modeling framework (AuCT-Sim) models real-time patients’ status changes 
using a state transition dynamic mechanism with a Markovian property. This structure 
assumes that patients’ state changes are mutually independent, and patients would transit 
to states that are highly correlated with their health status. In this way, AuCT-Sim simulates 
real-time changes of patients whose specimens have arrived in the facility for production 
uses. 
Beyond the dynamic of “Patient Status,” AuCT-Sim also models the dynamic of 
specimen quality. Each specimen also has its own “Quality Check” categorical variable 
that may take a value among “Pass,” “Fail,” and “Pre-certified.” Any product that fails a 
quality check cannot be replaced by another product; a new request for the patient's 
specimen is necessary whenever the value of this variable changes to ‘Fail.’ The change 
happens when a quality control procedure is performed.  
Justifications of quality failure in AuCT-Sim rely on a “Quality” index valued as 
real numbers between 0 and 1, where 1 indicates that the product is in its “perfect” state 
and 0 indicates the product is totally unusable. The model assumes that the initial quality 
of the specimen follows a predefined distribution upon its arrival. As a specimen may 
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deteriorate over time, the “Quality” index of the specimen will decrease at a random speed, 
where the exact decreasing amount sampled from a distribution is provided by empirical 
knowledge. This deterioration can be the result of cells failing to expand, or the loss of 
sterility, viability, and potency during production.  For example, whenever the product is 
exposed to the outer environment (e.g., to take samples for quality control tests or to be 
transferred from one container to another), there is a small chance that contamination may 
happen, and hence “Quality” will be set to 0. The probabilities of contamination at each 
manufacturing and quality control procedure are preset based on empirical data. In any 
quality control test, the value of “Quality” will be compared against a preset criterion of 
that test. Once the “Quality” index is lower than required, the value of “Quality Check” 
changes to “Fail”; otherwise, the “Quality Check” stays the same. 
The inventory management subsystem has a communication port that links to 
supplier nodes in the supply chain network. There can be multiple inventory replenishment 
policies preprogrammed. The subsystem can switch between different policies based on a 
certain global event. For example, the reagent suppliers may forecast a supply change. The 
manufacturing facilities in the affected distribution region may switch to a more 
conservative reagent replenishment policy. 
Similarly, the resource management subsystem can also communicate with events 
outside of the facility. In a case of demand surge (which may be caused by a new indication 
approval or reimbursement allowance, for example), the facility may ask the operators to 
work overtime until more operators are recruited. There are also communication ports at 
each quality control step, as they could be out-sourced under certain circumstances. 
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It should be noted that the microscale simulation of a single manufacturing facility can 
be packaged into a standalone tool. For example, the demand from clinics can be simulated 
by a Poisson process or extracted from historical data. Similarly, other communication 
ports can be fed by random number generators or historical data. The standalone 
manufacturing facility tool could be used to support decision-making at the microscale. 
Examples of such decisions include:  
• What is the bottleneck of the production capacity? 
• What is the relationship between manufacturing configurations, batch capacity, 
and turnaround time? 
• How does a manufacturing innovation impact patient benefit? 
2.1.3 Macroscale simulation 
The macroscale simulation is designed to model the allocation of multiple 
manufacturing facilities, which can have different configurations at the microscale level, 
and the connection with clinics and suppliers as a supply chain network. Figure 2.2 shows 
the three archetypes of the supply chain network designs: the centralized production model, 
the regional manufacturing hubs model, and the "point of care" production model. There 
can also be hybrid solutions that use more than one basic design type in different regions 




Figure 2.2 Three supply chain network designs 
 
 The macroscale simulation for the supply chain can generate valuable information 
related to the entire AuCT industry or the entire AuCT supply chain network. A few typical 
questions that could be answered by this tool are listed below: 
• What are the strengths and weaknesses of each of the three supply chain network 
designs? 
• What are the optimal number and placement of manufacturing facilities given 
specific demand distribution over the country or globally? 
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• What are the risk mitigation strategies to counter an unexpected event, such as a 
reagent supply disruption, and what are the costs and performance of these 
strategies? 
• How will policies and regulations affect the efficiency and the robustness of the 
supply network? 
2.1.4 Multidimensional key performance indicators (KPIs) 
The AuCT-Sim generates and records comprehensive manufacturing and 
distribution data from each simulation run. The statistical indicators output can be divided 
into three subgroups: time, efficiency, and cost. Different stakeholders may have different 
weighting factors assigning to these indicators when evaluating the overall performance.    
2.1.4.1 Time-related indicators 
The fulfillment time is composed of manufacturing time and distribution time. Each 
indicates the performance of the manufacturing facility and the supply chain network, 
respectively. The manufacturing time is the time between when the specimen arrives at the 
manufacturing facility and when the product leaves the facility for delivery. It can be 
further divided into four components: processing time, quality control time, queue time, 
and outage time.  
The processing time is the necessary time to produce the AuCT product, including 
upstream processing, cell expansion, and downstream processing. This component is 
insensitive to operational decisions.  
The quality control time is the time spent on actions to assure the quality of the 
product, including the acceptance check, the releasing check, and the intermediate quality 
control assays. The acceptance check and the releasing check are done before and after the 
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production process. The intermediate quality control steps are distributed at different time 
points during the production to prevent the risk of wasting resources on continuing 
processing products that have fallen below the necessary quality requirements. Figure 2.3 
shows three strategies to arrange the in-process quality control steps. Based on the relative 
importance of reducing production time and reducing waste risk, decision-makers can 
make quality control steps and production steps overlap in time at different degrees. 
Therefore, the overall quality control time is partially controllable by the manufacturer 
depending on the configuration. 
 
 
Figure 2.3 Different quality control strategies 
 
The queue time is primarily determined by the demand and the manufacturing 
capability of the facility. Different queueing policies can also have impacts on the average 
queue time. The goal of any manufacturing facility should be to make the queue time as 
short as possible without reducing the utility of resources.  
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The outage time is the wasted time caused by various unexpected events, such as 
machine breakdown, power outage, reagent supply disruption. A special case in cell 
manufacturing is contamination. Any operation involving the interaction of the product 
and the environment will bring the risk of contamination. The time previously spent on 
contaminated products is wasted. A new specimen must be requested, and the production 
must start over.  
The distribution time is determined by the design of the supply chain network, 
which has different aspects including the amount and placement of manufacturing facilities, 
the methods and routes of delivery, and the real-time conditions of transportation. The goal 
of optimization is to minimize the distribution time within the constraint of the total cost. 
Note that the total cost is affected by the cost of transportation and additional factors. For 
example, the location of a manufacturing facility determines the rent, tax, and salary 
criteria of its employees. In practice, the location of a manufacturing facility is usually 
assessed by factors including cost, patient accessibility, the demand distribution. 
2.1.4.2 Efficiency-related indicators 
The efficiency of the microscale model refers to the utility of machines, reagents, 
labor, and spaces. Any idle resource implies a fraction of the cost that can be potentially 
reduced. However, as there is intrinsic uncertainty of the AuCT industry and the product 
is for therapeutic use, it is necessary to reserve some resources for contingencies. The 
optimal ratio of reserved resources is difficult to determine solely via the use of the 
simulation model. Decision-makers can pre-set various scenarios to find the balance 
between reserved resources and uncertainty handling. Once the balance point is determined, 
the manufacturer can use the model to find a facility setting that can achieve the desired 
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utility of different resources. The effects of various disaster scenarios can also be verified 
using the simulation model. 
At the macroscale, efficiency refers to the fulfillment rate of a facility and the 
marginal utility of a new manufacturing facility at a specified location. Specifically, it 
measures the increase in the patient benefit, especially patient accessibility, caused by 
adding a new manufacturing facility. The efficiency of the supply chain network is low if 
the service areas of many manufacturing facilities substantially overlap.  
2.1.4.3 Cost-related indicators 
The AuCT-Sim collects cost data for each product during the simulation run and 
uses the data to calculate two cost indicators: “cost per batch” and “cost per year.”  Table 
2.1 summarizes all indicators that compose the output of the AuCT-Sim. Since different 
users may have different emphasis on these indicators, the Key Performance Indicator (KPI) 
is essentially a multidimensional variable with user-assigned weighting factors. The 





Table 2.1 Key performance indicators calculated by the simulation model 
    Relevant Stakeholders 






























































Fulfillment time           
 > Manufacturing time             
 > > Production time                
 > > Quality control time               
 > > Queue time              
 > > Down time                








Machine utility                
Labor idle time               
Reagent reserve               
Unused inventory space                
Fulfillment rate              
Increased service coverage              
C
os
t Cost per batch               
Cost per year               
 
 
2.1.5 Stochastic settings and highly customizable framework 
AuCT-Sim framework can model a large number of stochastic processes in cell 
manufacturing. These processes include patient demand arrival process, patient health 
status transition process, specimen viability decay process, cell deterioration/pollution 
process, production equipment ON-OFF process. All the statistics are highly customizable, 
which allows the user to modify many parameters before and during each simulation run. 
These settings may be changed according to the historical data from the specific facility. 
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Alternatively, the historical data can be used directly as the input with a tabular format. 
Case studies may also be developed with the AuCT-Sim by modifying various aspects, 
such as the amount and placement of the clinics, manufacturing facilities, and the reagent 
suppliers, the route of manufacturing and quality control procedures, the fluctuation in 
demand and supply, and the quality control thresholds. 
The AuCT-Sim may be configured and validated to be a digital representation of 
an existing facility or a hypothetical facility in a preset scenario. Validation approaches to 
simulations include subjective expert reviews and objective input-output statistical tests 
(Sargent, 2013). To assess whether AuCT-Sim produces an equitable or reasonable 
representation of a manufacturing facility, a three-step validation routine (Naylor & Finger, 
1967) may be utilized. 
1) Cell manufacturing process experts who are knowledgeable with the system 
review the validity of this simulation model based on the model animation; this 
system animation demonstrates manufacturing details, including the production 
flow from specimen arrival to final shipment, the consuming/replenishing of 
reagent inventory, the utilizing and releasing of recyclable recourses (bioreactors 
and technical operators), the failure and repair of bioreactors, and all quality 
control sampling and testing. 
2) Validate model assumptions: All key assumptions must be revealed to review by 
subject matter experts for a validation check. For assumptions related to input 
data/distribution(s), implementers should collect related data for statistical tests. 
3) Input-output analysis: Output from the system was compared to model outputs 
with an identical set of input conditions. Given the validated input 
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parameter(s)/distribution(s), The simulation output should not be significantly 
different from the physical system output. With data collected from both 
simulated and physical production systems, the implementers should conduct a 
nonparametric statistical test to claim the similarity between the two systems. 
Wilcoxon signed-rank test and Mann-Whitney U tests are two commonly used 
methods to claim statistical similarity or significant difference.  
2.2 Extension to allogeneic cell therapy simulation platform 
 Based on the AuCT-Sim, an agent-based simulation framework that maps the 
manufacturing and supply chain process for allogeneic cell therapy manufacturing both at 
a single facility level and in the context of a larger supply chain network (AlloCT-Sim) 
was also developed. The simulation framework includes modules for manufacturing 
process design, quality control procedures, inventory management, and resource 
management. The agent-based simulation framework provides a good opportunity to track 
the cost of manufacturing and distributing each product. An industry user can use this 
function to support operational decision-making, whereas an academic user can evaluate 
the impact on the cost of any novel technology.  
 After defining the parameters for the manufacturing system and providing inputs 
into the simulation framework, users can see simulated results of the operating cost by 
categories, cost of goods, manufacturing failure rate, estimated final product quality, 
capacity, and resource utilization during any time of production or other customized 
performance indices that are of interest to the users. Users can then use these results to aid 
in decision-making for process design, facility planning, and developing what-if scenarios 
for any potential disruptions.  
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2.2.1 Structure of simulation framework 
 The simulation framework has three components, representing activities at three 
tiers: suppliers, manufacturers, and clinics. The three components are sourcing and 
procurement model, manufacturing process model, and distribution model. The first two 
components are joined by a receiving inventory node, and the last two components are 
joined by an outgoing inventory node. Each component can be used as a standalone 
simulation tool to study intra-tier problems. When integrated, the three components form 
a complete supply chain simulation tool that can be used to support industry-level decision-
making.  
2.2.2 Sourcing and procurement model 
 The sourcing and procurement model simulates the interactions between a 
manufacturing facility and the suppliers of raw materials, reagents, and consumables. 
Various types of starting materials, ancillary materials, and consumables are used in an 
allogeneic cell therapy manufacturing facility, including cells, gene editing tools, beads, 
recombinant proteins, human plasma-derived media supplements, cryopreservation 
solutions, cryovials, bags, and other vessels, as well as other components that a 
manufacturer may have on its bill of materials. The company’s inventory management plan 
may have different stock policies for each component. In the sourcing and procurement 
model, each material type will select from a set of commonly employed inventory control 
policies, including Periodic Reviewed Base Stock, Periodic Reviewed s-S, Continuous 
Reviewed Economic Order Quantity (EOQ), and Continuous Reviewed s-S. All policies 
are parameterized and allow the user to define the parameters. A list of selectable inventory 














Culture media Base Stock Level 130 units 
Delivery lead time 7 days +/- std 
Recorder frequency every 7 days 
Cost of delivery 10% of the material 
cost 
Cost of acceptance quality 
check 





Culture media Inventory-up-to level 130 units 
Reordering threshold 30 units 
Delivery lead time 7 days +/- std 
Recorder frequency every 7 days 
Cost of delivery 10% of the material 
cost 
Cost of acceptance quality 
check 





Culture media Reorder threshold 30 units 
Fixed reordering quantity 100 unit 
Delivery lead time 7 days +/- std 
Cost of delivery 10% of the material 
cost 
Cost of acceptance quality 
check 





Culture media Reorder threshold 30 units 
Inventory-up-to level 130 unit 
Delivery lead time 7 days +/- std 
Cost of delivery 10% of the material 
cost 
Cost of acceptance quality 
check 




 The sourcing and procurement model component forms part of the holistic supply 
chain model, but it can also be used independently to address problems that only involve 
supply chain-related issues. For example, the users may investigate cost efficiency and 
supply resilience under different stock policy combinations. 
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2.2.3 Manufacturing process 
 The manufacturing process model simulates the activities inside the manufacturing 
facility. The primary subgroups of activities in a cell manufacturing facility include 
manufacturing procedures, quality control procedures, and resource management. Figure 
2.4 shows the flow chart of the generalized cell manufacturing process and how the 
resources are allocated to each step. The specimens from donors arrive at the top-left corner 
and go through the acceptance check and the upstream processing. Then the specimens 
enter a queue, waiting for bioreactors, operators, and reagents to be assigned by the 
resource management subsystem. After the necessary resources are allocated, the 
specimens come to the expansion stage, where several quality control tests are performed 
at different time points over the entire course. After the expansion, the products go through 
the downstream processing and release check subsequently. At last, qualified products are 








 There are a huge number of parameters needed to comprehensively define a cell 
manufacturing facility. However, in a typical decision-making scenario, only a subset of 
all the parameters would have significant relevance. The importance of each parameter 
depends on the specific problem of interest. In the generic simulation, a set of important 
parameters for common decision-making scenarios are selected. In the meantime, every 
agent is kept in the simulation expandable so that more detailed parameters can be called 
if they become important to the problem of interest. For example, if the total cost of human 
labor is concerned, only the “average salary” and the “total number of employees” will be 
used for calculation. However, if the problem is to compare the costs on technical staffs 
and management staffs, a set of more detailed parameters, including the number and 
salaries of different staff types, will be used. 
 The core parameters used in the generic simulation can be divided into six 
categories, according to QbD development strategies: Task, Employee, Equipment, 





Table 2.3 Core parameters used in the generic simulation 
Name of parameter Category Example value 
Campaign size Task 8 batches per month 
Dose per batch 100 
Number of operators Employee 6 
Average tenure length 10 years 
Shift length 8 hours 
Number of working days per year 261 
Cost of training … 
Average annual salary $100,000 
Number of non-operating staffs 
(QC, QA, supervising, admin, …) 
20 
Total number of bioreactors Equipment 10 
Probability of bioreactor breaking down 1% per day 
Time needed for maintenance 5 days 
Starting cell count Specimen 2.25E9 
Percent of CD4/CD8 enriched cells 27% 
Gene editing efficiency 30% 
Number of expansion fold per day 8 
Cell loss at each unit ops 10% 
Probability of contamination during unit 
ops 
0.1% 
Starting cell viability uniform (80%) 
Daily rate of cell losing viability triangular (0%, 0%, -2%) 
Operator required for upstream 
processing 
Operation 3 
Duration of upstream processing 2-4 days 
Operator required for expansion 2 
Duration of expansion 10-12 days 
Setup time for expansion 3 hours 
Active ops 4 hours every two days 
Operator required for downstream 
processing 
3 
Duration of downstream processing 12 hours 
Duration of acceptance test 3 hours 
Viability threshold of acceptance test 87.675% 
Duration of intermediate QC 1 day each 
Viability threshold of intermediate QC 1 84.627% 
Viability threshold of intermediate QC 2 83.224% 
Viability threshold of intermediate QC 3 81.820% 
Duration of release test 30 days 
Viability threshold of release test 70% 
  
Cost of QC $30,000 per batch 
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Cost of viral vectors per batch Material $ 9,000 
Cost of culture media per batch per day $400 
Cost of activation $700 
Cost of reagent for purification $300 
 
 
2.2.4 Distribution and logistics 
 The distribution of allogeneic cell therapy is similar to the distribution of regular 
drugs. To simulate the distribution and calculate the time and costs, necessary information 
should include the number of warehouses and clinics in the supply chain network, the 
distance, delivery mode, time, and costs between each warehouse site and each clinic site. 
The requests generated from each clinic follow a Poisson distribution. Requests always go 
to the nearest warehouse with available therapies. There can also be hybrid solutions that 
use more than one basic design type in different regions or under different situations. 
2.3 Demonstrative case studies for autologous cell therapy 
A virtual CAR-T manufacture facility was built based on system specifications 
collected from an AuCT production facility with demonstrative case studies described in 
this section. A detailed case study for the design of an AlloCT production facility will be 
presented in Chapter 4. 
2.3.1 Case 1: Optimal reagent base stock level 
The aim of this case study was to determine an optimal base stock level for reagents 
in order to reduce the possibility of stock-out events while eliminating unnecessary 
inventory redundancy. In the simulation, the batch of all needed reagents was treated as a 
single unit of reagents. All other system specifications were fixed, while the base stock 
Table 2.3 Continued 
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level was varied from 10 to 150 in 10 step increments. Each base stock level is tested ten 
times with randomly generated starting seeds. To ensure appropriate comparison across 
different base stock levels, each of the ten times of simulations with different base stock 
levels is grouped as a master replication. Starting seed of each master replication must be 
kept identical to ensure that all event scenarios are the same except the variable of interest 
(base stock level). 110 data points collected from AuCT-Sim are scattered in Figure 2.5. 
The figure shows that average production lead time is monotonically decreasing as the base 








2.3.2 Case 2: Mitigating the risk and impact of supplier disruption 
The target of this research case study was to investigate several system 
performances when a supplier disruption occurred and later recovered, with different 
combinations of the bioreactor and technical operator quantities. The system can then assist 
the designer in determining how many bioreactors and operators are needed to mitigate the 
risk of supplier disruption. Supplier disruption is a likely and severe risk for 
biomanufacturers. In 2017 alone, the cell therapy industry witnessed a saline shortage due 
to Hurricane Maria and a severe flu season (Jarvis, 2018; Wendelbo & Blackburn, 2018), 
as well as the shutdown of a major cell therapy supplier due to sterility issues (Palmer, 
2017). The case study investigates how the system performance recovers after the 
occurrence of supplier disruption. 
Figure 2.6 depicts queueing lengths of different facility designs over the horizon of 
500 days. Queue lengths of every facility increased after the supplier disruption occurred 
on day 200, and queue lengths diminish after resuming the reagent supply on day 260. The 
facilities with 20 bioreactors, 12 operators, and the facilities with 15 bioreactors, 9 
operators (black line and red dotted line, respectively) are able to recover to the normal 
state within 42 and 64 days, respectively. While for the facilities with 11 bioreactors, 7 
operators, and the facilities with 11 bioreactors, 6 operators (purple line and blue dotted 
line, respectively), these fail to recover after the reagent disruption. Moreover, facilities 
with insufficient bioreactors or operators would also lead to further mild increments in their 
queue lengths. This fact is because of the congestion of pending requests, as the constrained 





Figure 2.6 Trends of queue lengths for different facility designs 
 
Figure 2.7 summarizes a few of the KPIs used to evaluate system performances for 
cases with 11 bioreactors and 7 operators (6a) and 20 bioreactors and 12 operators (6b). As 
shown in Figure 2.7a, when 11 bioreactors and 7 operators are equipped, the supply chain 
fails to recover after the supplier disruption from Day 200; the bioreactor utilization is kept 
at 100%, and the proportion of patients who canceled their production increases eventually 





Figure 2.7 System performance under selected equipment and labor force specification 
 
While for the system equipped with sufficient bioreactors and operators (20 
bioreactors and 12 operators in Figure 2.7b), the bioreactor utilization rate recovers to 
normal on Day 334. The proportion of patients who canceled their production barely 
increased by about 3 percent and then mildly recovers to normal by the end of the testing 
period. The proportion of patients queued increases to 29% after the disruption occurred, 
but is able to recover quickly to normal by day 320. 
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By carefully tuning bioreactor and operator quantities, the decision-maker can 
visualize the recovery ability under given system specifications and design strategies to 
mitigate the risk of process disruption.  
2.4 Discussion 
As an emerging industry, cell therapy manufacturers must engage in data-driven 
planning before expansion.  However, high uncertainty, the steep upfront investment, and 
the lengthy trial duration make practical verification of planning scenarios impractical. 
Running computational experiments with a simulation model becomes an economical 
alternative for several reasons.  
Firstly, the simulation platform generates and records data comprehensively with 
perfect repeatability. In real-life experiments, some critical data could be overlooked at the 
beginning due to the lack of fundamental knowledge. With computational experiments, all 
data are stored and can be regenerated. Although some parameters are stochastic, recording 
the seed of the random number generator ensures that repeats generate the same “random” 
values.  
Secondly, factors in the platform are controllable. In real-world manufacturing 
demonstrations, it is challenging, if not impossible, to isolate one particular factor from 
numerous factors in a cell therapy manufacturing facility to test its effect. The effect can 
be confounded with the considerable variability in other factors. With simulation, it is easy 
to vary one factor in multiple computational experiments to evaluate its actual effect.  
Thirdly, the simulation platform can be used to investigate hypothetical scenarios. 
The simulation can provide insights into events that are too large in scale to set up a real-
life experiment, such as a hurricane-caused reagent supply disruption that affects the entire 
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east coast of the US. Decision-makers can use this decision support system (DSS) to test 
different risk mitigation strategies and be prepared to counter similar events in the future. 
Lastly, the simulation platform can highlight and clarify ethical tradeoffs inherent 
in the complex CAR-T cell manufacturing processes. The focus of supply chain 
optimization is typically and understandably meeting anticipated demand while 
minimizing the cost of goods. Decisions about the number of manufacturing facilities to 
use, their locations, and their capacity, among many other factors, also affect the extent to 
which patients or subsets of patients can access a specific therapy safely, reliably, and 
promptly. Such information is critical to firms developing strategies to scale their 
production and incorporating potential contingencies into their planning processes. Supply 
chain simulation, combined with information on the possible size, location, and prognosis 
of patient populations, in particular, may offer a uniquely powerful approach to proactively 
identify concerns relevant to the commercialization of novel cell therapies early in the 
development process and proactively address them. 
Because the framework is highly customizable, it is a versatile tool that can help 
with the study of various subjects. Future research directions following this work include: 
• What is the optimal patient priority policy for compassionate care cases? 
• What is the best transshipment strategy for the robustness of the supply chain 
network? 
• Which inventory replenishing policy is the most suitable for a cell therapy facility, 
considering the possibility of supply disruptions?  
• How to make policies to encourage manufacturers to expand into regions with 
low patient accessibility? 
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• What are the marginal effects of technical innovations in different manufacturing 











 Although more and more cell therapies are getting approved by FDA and other 
regulatory agencies around the world, the treatment itself remains prohibitively expensive 
for most of the targeted patients. As of March 2021, there are five FDA-approved CAR-T 
therapies for treating different types of blood cancer, including leukemia, lymphoma, and 
most recently, myeloma (U.S. Food and Drug Administration, 2021) for both children and 
adults. The cost of these therapies ranges from $373,000 to $475,000 (Table 3.1). 
 
Table 3.1 FDA approved CAR-T therapies for blood cancers as of April 2021 
Product Company Year Approved Price 
Kymriah Novartis 2017 $475,000 $373,000 
Yescarta Gilead/Kite 2017 $373,000 
Tecartus Gilead/Kite 2020 $373,000 
Breyanzi BMS 2021 $410,300 
Abecma BMS & Bluebird Bio 2021 $419,500 
 
 
 However, the price of the drug itself is just a part of the total treatment cost. A 
typical CAR-T treatment for blood cancer includes pre-treatment testing, apheresis, 
conditioning, treatment, post-treatment monitoring, and post-discharge monitoring. These 
processes result in a lengthy hospital stay and the use of many other services and medicines. 
The combined cost of the drug and these related care is estimated to be somewhere between 
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$463,500 - $968,000, close to one million dollars for some patients (Rockoff, 2018). The 
unprecedented high cost of the treatment has created great financial strains for hospitals, 
health insurers, and patients themselves as they figure out how to cover the astronomical 
cost. Many health insurers are only approving CAR-T therapies on a case-by-case basis, 
and a lot of the patients have turned to online medical crowdfunding, such as the use of the 
GoFundMe website, to secure funding for the medical expenses incurred during the 
treatment (Ho, Oso, & Levine, 2019). Therefore, understanding the manufacturing cost and 
its relationship to price is the first step to make the treatment more affordable.  
 This chapter will establish a cost analysis framework for understanding the cost of 
cell therapy, compare and analyze different cost analysis models, set the benchmark for 
manufacturing costs, and integrate cost modules into the existing simulation platform. 
3.2 Understanding cell therapy cost 
3.2.1 Cell therapy cost overview 
 Based on the development cycle of a pharmaceutical product, the overall cost and 
investment for developing and producing a cell therapy product can be broken down into 
three major categories: development cost, manufacturing cost, and operation cost (Farid, 
Baron, Stamatis, Nie, & Coffman, 2020). A breakdown of what these costs entail is listed 




Table 3.2 Major cost categories in the development cycle of a pharmaceutical product 
Development Cost Manufacturing Cost Operation Cost 
R & D Cost Direct Cost Logistic & Distribution 
Cost 
Clinical Trial Cost Indirect Cost Sales and Marketing Cost 
Factory Capital Cost Other Cost (Failure Cost) Administrative Cost 
Regulatory Compliance 
Cost 




 Development costs are the costs incurred to the manufacturer before the product 
hits the market. These costs include the expenditure for research and development (R & D) 
of the therapy, capital costs incurred for building the manufacturing facilities and setting 
up the logistic network, costs for designing and running clinical trials, including 
manufacturing of the therapy for the clinical trial, as well as the costs associated with 
ensuring the drug design, manufacturing, and clinical trial processes are compliant with the 
regulation of FDA and other regulatory bodies.  
 Manufacturing costs can be divided into direct costs that are directly tied to the 
specific batch manufacturing process, indirect costs that are not tied to the specific 
manufacturing process, and the costs incurred for the failed batches that cannot be sold to 
the patients.  
 Operation costs are the costs incurred outside the manufacturing facilities when the 
product is released to the market. These costs include the logistic and distribution costs for 
getting the cells to the clinic, sales and marketing cost for raising awareness and promoting 
the drugs to the targeted patients, administrative costs, as well as patient administration 
cost for training and assisting hospitals on how the drug should be administered.  
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 There is no standard for how the costs need to be categorized, and different cell 
therapy companies can have different cost categories among each other. Some cell therapy 
companies categorize logistic costs as parts of manufacturing costs instead of operation 
costs. 
3.2.2 Manufacturing cost breakdown 
 As the purpose of this research is to help cell therapy manufacturers improve their 
production and logistic operation, the thesis will focus on the modeling of cell therapy 
manufacturing costs within the manufacturing facility. Manufacturing costs for cell therapy 
production mainly come from the following major sources: personnel, raw material and 
supplies, quality, facility & maintenance cost. Each of these cast categories has some 
components that contribute to the direct costs, indirect costs, or failed costs. Some of the 
cost components for each of these cost categories are listed in Table 3.3.  
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Table 3.3 Detailed breakdown of manufacturing costs 
 Direct Cost Indirect Cost 
Personnel 
Operator and quality 
control labor wage and 
benefit 
Operator and quality control 
training, pension, overhead, 
supervision and management 
wage and benefit 
Utilities Electricity, water, natural gases use during activity 
Electricity, water, natural 
gases use at rest 
Facility & 
Maintenance 
Corrective maintenance Preventive maintenance, 
rent, investment amortization 
(non-cash cost) 
Quality 





Materials and Supplies Raw material and reagent, cleanroom garments 
Office and lab supplies, 
cleanroom garments 
Cost of Failed Batch (failed quality testing, contamination, or past shelf life) 
 
 
 The price for some of the cost items, such as cleanroom garments and utility costs, 
are fairly transparent and consistent. They are easy to look up in the marketplace, and the 
price does not vary much across different regions, while some other costs are more elusive 
and can vary a lot between factories. For example, the cost for training cell therapy 
operators is dependent on the skill set of the new hire and how much resources the 
manufacturer is willing to dedicate for training, making it hard to estimate and are 
determined case-by-case. All cost components are categorized into three groups based on 
their transparency and variation among different companies (Figure 3.1):  
• Category 1 Cost, where the cost is transparent and fairly consistent across the 
industry. This might include equipment and starting materials. 
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• Category 2 Cost, where the cost lacks industry data or has a large range between 
companies. This might include gene-editing tools, QC testing, some ancillary 
materials. 
• Category 3 Cost, where the cost is either proprietary or depends on company 
policies. This might include the upstream/downstream process itself.   
 
 
Figure 3.1 Categorizing cost items based on the opaqueness and degree of variation 
   
3.2.3 Cost estimation methodology 
 Cost items with different transparency require different methods to obtain or 
estimate the process information. These methods can include: 
• Publicly available information (news, press release, financial disclosure) 
• Online marketplace 
• Market report & analysis from market research companies 
• Industry survey report 
46 
 
• Direct correspondence with manufacturers 
• Commercial database 
• Simulation software 
• Heuristics and estimation factors 
• Similar products or historical data 
• Best guess 
 The list is ordered based on the transparency and the accuracy of the cost items. 
Researchers doing cost estimation should start with searching for publicly available 
information and gradually move down the list.  
 For example, the facility construction costs of a CAR-T manufacturing facility with 
an annual production capacity of 5,000 batches can be found from publicly available 
information on Kite’s SEC filings (Kite Pharma, 2016) to be around $26 million for their 
El Segundo manufacturing facility. Many equipment costs can be found by searching 
online marketplace such as Alibaba.com or requesting a quote from equipment 
manufacturers. Researchers can also try reaching out to the cell therapy manufacturer 
directly to ask for an estimation of certain cost items or look up industry survey reports 
based on the response from actual cell therapy manufacturers to estimate many of the cost 
items (Lipsitz et al., 2017). If there is an additional budget for cost modeling, researchers 
can purchase commercial market reports from market research companies that contains a 
lot of cost information. There are also commercial databases and process simulation 
software, such as Biosolve Process® that contain many cost item information. 
 For cost item information that cannot be directly obtained, researchers can use 
heuristic and estimation factors to estimate the cost. Lang factor is a very popular 
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estimation method widely used in industrial engineering to calculate the capital and 
operating costs of a manufacturing plant based on total equipment cost. Many cost analysis 
research articles have used a Lang factor of 23.67 to estimate the facility costs for CAR-T 
manufacturing facility (Hassan et al., 2015; M. Jenkins, Bilsland, Allsopp, Ho, & Farid, 
2016; Pereira Chilima, Moncaubeig, & Farid, 2018; Simaria et al., 2013). If none of these 
methods are available, researchers can resort to finding the cost items for similar products 
or historical data for estimating costs, such as using the quality control cost of 
mesenchymal stem cells to estimate the quality control cost of CAR-T cells.  
3.2.4 Variations in cost estimation 
 Many academic research articles have been the cost of goods (COGS) estimation 
of different cell therapy products. A list of the cost of goods estimation studies from peer-
reviewed journals is in Table 3.4 that includes CAR-T, MSC, iPSC, dendritic cells, and 
other lymphocytes that originate from either an autologous or allogeneic donor source. 
COGS are defined as the manufacturing cost for one dose of cell therapy. The COGS of a 
cell therapy product vary widely, ranging anywhere from $1,000 to $120,000. For 
autologous cell therapy, one batch can only produce one dose for the intended patient, 
while a batch of allogeneic cell therapy can be divided into several doses. Thus, the COGS 
of allogeneic cell therapy are usually lower than autologous cell therapy and are heavily 
dependent on dose requirements. For example, treatment for chronic low back pain requires 
around 10 million cells per dose (Pang, Yang, & Peng, n.d.), while treatment for systemic 
diseases such as GvHD or heart disease can require up to 1 billion cells per dose (Lazarus 




Table 3.4 List of COGS estimation for cell therapy products from peer reviewed 
literatures. Costs that are originally in other currencies are converted to USD 
Product COGS Reference 
Autologous CAR-T $78,720 (Lopes, Noel, & Sinclair, 
2020) 
Autologous CAR-T $58,200 (Spink & Steinsapir, 2018) 
Autologous CAR-T $95,780 (Harrison et al., 2019) Allogeneic CAR-T $4,460 
Allogeneic CAR-T $7,629 (M. J. Jenkins & Farid, 
2018) 
Allogeneic umbilical cord 
derived MSC 
$3,700 - $65,100 (Mizukami et al., 2018) 
Allogeneic MSC $485 - $1,750 (10M cells) 
$13,134 - $111,488 (1 B 
cells) 
(Pereira Chilima et al., 
2018) 
Allogeneic MSC $1,000 - $2,000 (Harrison, Medcalf, & 
Rafiq, 2018) 
Autologous dendritic cells $51,301 (Lopes et al., 2018) 
LV induced autologous 
hematopoietic stem cells  





(ten Ham et al., 2020) 
Allogeneic pp65-specific T 
cells 
$27,371 
Allogeneic MSC $36,461 
Allogeneic stem cell-





Allogeneic limbal stem 
cells 
$28,463 





 Even for the same cell type, the COGS estimation can have big variations. The three 
COGS estimations for autologous CAR-T cited in Table 3.4 range from $58,200 to $95,780. 
Some of the variations result from different factory sizes and designs, different 
manufacturing routes, equipment choices, and personnel management, while some of other 
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variations result from different valuations for the same cost items. Table 3.5 lists the major 
differences in the three COGS estimation methods for autologous CAR-T cells published 
in peer-reviewed journals. Some of the cost item values are approximated from the figures 






Table 3.5 Comparison of COGS estimation studies for autologous CAR-T cells 




(Lopes et al., 2020) 
Market 




captured 30% blood 
cancer market, and 
the provider captured 
35% of the CAR-T 
market 
 















Total manufacturing cost 
Total annual cost $1.72 B $87.3 M $800 M 
Total cost per 
dose/COGS 
$95,780 $58,200 $78,720 
Largest cost 
category 




Material and supply 
(67% COGS) 
DETAILED COST CATEGORY 
Labor 
Average annual 
cost per employee 
$90,000 $155,000 $97,333 
Number of staff 160 400 1654 
Total labor cost $14.4 M $62 M $161 M 
Labor cost per dose $803 $41,322 $15,691 
Percent of COGS 1% 71% 19% 







operator, QA, QC, 
supply chain, and 
facility manager 
compensation 
Material and supply 
Total cost $1.1 B (mfg) 
$0.55 B (QC) 
$15.7 M $530 M 
Per dose cost $62,257 (mfg) 
$30,647 (QC) 
$10,476 $51,744 
Percent of COGS 65% (mfg) 
QC (32%) 
18% 67% 
Facility and transport 
Total cost $17.2 M (facility) 
$34.6 M (transport) 
$10.5 M (facility) $108.1 M (facility) 
$7.7 M (transport) 
Per dose cost $960 (facility) $6,984 (facility) $10,540 (facility) 
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$1,920 (transport) $750 (transport) 
Percent of COGS 1% (facility) 
2% (transport) 




N/A $37 M $277 M 















 The variations in COGS estimation comes from having different estimation for 
market demand and production capacity, having different sources for cost item valuation 
and different cost items included in each category. Spink & Steinsapir has labor as the 
largest cost category accounting for 71% of the total COGS, while the other two models 
pegged labor for only 1% and 19% of COGS mainly due to different definitions of labor. 
Only Spink & Steinsapir included clinicians, couriers in the model, while Harrison et al. 
only included operators in the cost model and has QA, QC personnel separated in its own 
category. Spink & Steinsapir also has a much lower material cost compared to the other 
two models as they assumed a very low viral vector cost that only accounts for 3-4% of 
material cost, while the other two models assumed a much higher viral vector cost that 
account for more than 20% of material costs. 
 Using cost item data from all the published literature featured in Table 3.4, as well 
as data collected directly from cell therapy manufacturers and other sources, a set of 
possible ranges for the total cost of each cost category in autologous CAR-T manufacturing 
was determined and shown in Figure 3.2. In the figure, the top and bottom boundaries of 
the bar graph represent the maximum and minimum cost for that cost category, with the 
Table 3.5 Continued 
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blue line denoting the estimated industry average cost using the simulation platform that 
will be described in detail in the next section.  
 
 
Figure 3.2 Variation in cost per dose for each cost category for autologous CAR-T 
 
 The material cost has the largest variation among all cost categories, followed by 
labor and then facility cost, while transport has the smallest variation. Cell therapy 
manufacturers can compare their cost with the range and determine if their cost is at a 
higher or lower position compared to the rest of the industry. 
 As the material cost has the largest variation, it has the largest potential for cost 
reduction. The material cost is highly dependent on the size of the supply base and the scale 
of the supplier. Finding a large supplier with a lot of competitors can greatly reduce the 
material cost and overall manufacturing cost.  
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 Manufacturers with a large labor cost should focus on improving labor utilization 
rate, cross-train and share operators with other production lines, and look for possible ways 
to outsource many production functions, such as outsource viral vector production, some 
QC tests, and distribution to third parties. 
3.3 Cost modeling 
 All the cost modeling described in the previous section is developed on a 
framework and does not adequately capture the stochasticity and complexity of the 
manufacturing process. To account for the variation in cost estimation and help cell therapy 
manufacturers better estimate the cost of their production facility, this research will 
integrate a cost modeling module into the simulation platform and establish a benchmark 
for the cell therapy manufacturing cost that can help manufacturers ensure a cost-effective 
design of the production facility. 
 To establish a benchmark for each cost item, detailed cost information was 
collected from published literature, academic and industrial cell therapy manufacturers, 
and suppliers and stored in a database containing over 300 cost items for different cell 
therapies. Based on the variation and reliability of the cost items, the costs are categorized 
as Category 1, Category 2, and Category 3 cost described in the previous section. A 
different cost estimation model is employed for these different categories.  
 For the Category 1 cost components, the activity-based definitive cost model is used 
to determine cost. As the manufacturing and distribution of cell therapies can be affected 
by the patient status in real-time, the cost of an ongoing product will increase only when 
the particular resource is transformed into the added value of this product. For example, 
the cost of reagents, consumables, and labor hours of the upstream process is only added 
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to the overall manufacturing cost once the upstream process has been completed in the 
simulation model (Figure 3.3). If there is a discrepancy in the value of the cost items, either 




Figure 3.3 Definitive activity-based cost model for cell therapy 
 
 For the Category 2 cost components, the parametric-based cost model is used to 
estimate cost. A set of parameters that affect the cost component are first defined and 
assigned a range based on the information collected. The users will input the parameters, 
and the model will use heuristics to calculate the range of the cost component. For example, 
when the details of the logistics are not clear, users can estimate the logistic cost by setting 
the logistic cost to be 2% of manufacturing cost based on survey data.  
 The Category 3 cost components will be fully user-defined with reference and 
suggested value based on similar products or historical data.  
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 Based on these criteria, a cost modeling module is developed for the simulation 
platform. The simulation platform takes in a database file containing all the cost items 
involved in the particular cell therapy manufacturing process following the flowchart 
described in Figure 3.4. For example, a Category 1 cost item such as the viral vector used 
in the autologous CAR-T manufacturing process is coded in the following logic, the unit 
price of the viral vector is $8,492; one unit of the viral vector is used per batch; the viral 
vector is a part of the material cost; the price is definitive, and it is a direct cost in the 
manufacturing process; it is added during the upstream processing. The logic for a 
parametric cost item such as operator training cost is as follows: each operator receives one 
training session; it is part of labor cost; it is parametric; it is indirect; it happens once a year; 
it is 2% of annual salary, and the annual salary is $100,000. The training cost will be added 
to the total cost in the simulation once a year. 
 
 





 Following the logic described above, each cost item for autologous CAR-T is added 
to the simulation, and the simulation is run 1,000 times to produce a cost estimation for 
autologous CAR-T. Based on the simulation experiment results, the COGS for an 
autologous CAR-T product from a factory that produces 18,000 batches per year is 
estimated to be $83,309 ± $2,839 with an annual operating cost of $1.5 billion. Material 
accounts for the largest cost of 62%, followed by 19% labor cost, facility, and failure costs, 
with transport cost accounting for 1% (Figure 3.5). The result is consistent with other 
publications and fits well within the range of cost estimation described in Figure 3.2. 
 
 





 The cost for other cell types, including allogeneic MSC cells and iPSC-induced 
retina pigment epithelial cells, was also estimated using the same methodology. The cost 
estimation for the allogeneic MSC cells will be described in detail in Chapter 4. The 
summarized cost estimations for each three cell types are described in Table 3.6. 
 
Table 3.6 COGS estimation for different cell types 




















14 days 52 days 117 days 
Batches per year 1,800 400 100 
Doses per batch 1 250 100 
Cost per Batch $83,309 $70,901 $29,834 
Cost per Dose $83,309 $276 $298 
 
 
3.4 Demonstrative case studies 
 Demonstrative case studies are presented in this section to showcase how the cost 
module can be used to improve manufacturing cost 
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3.4.1 Case 1: Cost impact of resource underutilization 
 This study aims to understand how much additional costs are incurred when the 
manufacturing facility is underutilized and whether the manufacturer should focus on 
improving labor or equipment utilization.  
 In this simulation, an autologous CAR-T manufacturing facility with an annual 
production capacity of 1,500 batches is modeled to have an estimated COGS of $85,867. 
The facility requires a minimum of 34 full-time operators and 45 bioreactors to meet the 
production capacity based on simulation results. 
 However, the market demand is weaker than expected, and only around 1,000 
orders are placed in a year. If the facility keeps the same number of operators and 
bioreactors, the estimated COGS is estimated to increase to $87,566, increasing COGS by 
$1,763. If the facility can remove bioreactors to maximize utilization, it will save $196 per 
batch. However, if the facility can divert some of the labor to other production lines and 
maximize labor utilization, it will save $1,128 per batch on COGS. In this situation, the 
facility should focus on increasing labor utilization by diverting operators to other 






Figure 3.6 Impact of labor and equipment underutilization on COGS 
 
3.4.2 Case 2: Evaluating cost impact on new gene transfer technologies 
 The aim of this case study is to evaluate the viability and competitiveness of new 
gene transfer technologies for manufacturing cost reduction. 
 One of the most expensive cost items in CAR-T manufacturing is the cost of viral 
vectors. Current CAR-T manufacturers mostly use either lentiviral vectors or retroviral 
vectors to transfer the CAR gene to the T-cells. However, manufacturing of these viral 
vectors is extremely complicated, and they also require extensive safety tests to ensure they 
can be used safely for therapy purposes (Ausubel et al., 2012; Levine et al., 2017). There 
is a great demand for new gene transfer technologies that are easier and cheaper to 
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manufacture than viral vectors. One of the most promising new gene transfer technologies 
currently in development is the transposon/transposase plasmid DNA transfection 
(Ramamoorth & Narvekar, 2015). The manufacturing process is simpler and cheaper than 
the viral vector, and the transposon does not require extensive biosafety testing. However, 
a current drawback in the transposon system is that it requires a much longer cell expansion 
time than the current manufacturing process (Singh et al., 2011), increasing resources 
required for expansion.  
 In this case study, a simulated CAR-T manufacturing process is built for each gene 
transfer technology with lentiviral vectors,  retroviral vectors, and transposon system with 
the detailed input parameter included in Table 3.7. 
 








40.4% ± 20.5% 59.8% ± 21.4% 85.5% ± 8.1% 
Lead Time (days) 14 14 28 
Cost $8,492 $7,635 $1,400 
Failure Rate at 
10% efficiency 
threshold (%) 
7% 1.1% 0% 
 
 
 The average gene transfer efficiency for each method is calculated from 297 
published clinical trial data that use these systems for manufacturing CAR-T (Hartmann, 
Schüßler‐Lenz, Bondanza, & Buchholz, 2017). The costs of the viral vector and transposon 
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system are based on the data from published literature (Abou-El-Enein et al., 2013; 
Hudecek & Ivics, 2018; Spink & Steinsapir, 2018). If the gene transfer efficiency falls 
below 10%, the product will fail the QC process and be rejected. 
 After running the simulation, the result shows that although the transposon system 
can greatly reduce the gene transfer cost, it is not enough to offset the increase in expansion 
cost due to the longer expansion requirements (Figure 3.7). Using a transposon system 
currently will cause an increase of around $6,900 in COGS.  
 
 
Figure 3.7 COGS breakdown of CAR-T manufacturing using different gene transfer 
methods 
 
 Although the transposon system used in this study does not provide a cost 
advantage to CAR-T manufacturing, there have been many promising research efforts to 
enhance the transposon system that can reduce expansion time (Hudecek & Ivics, 2018; 
Monjezi et al., 2017). Using the simulation platform, it is calculated that the transposon 
system will be more cost-effective than the viral vector if the expansion duration can be 





Figure 3.8 Impact of expansion duration on the transposon system COGS 
 
3.4.3 Case 3: Centralized vs. decentralized manufacturing 
 The aim of this study is to develop a rudimentary network model to compare 
operation costs for building a centralized or decentralized manufacturing network in the 
US. The case study will use the Kymriah CAR-T product from Novartis as the basis to 
model the demand and logistic network for the simulation.  
 In this study, three different manufacturing networks are planned to meet an annual 
demand of treating 2,000 patients within the contiguous United States. The three networks 
include: 1) Building one centralized facility with a production capacity of 2,000; 2) 
Building two regional manufacturing hubs around the East and West Coast; 3) Building 
ten decentralized facilities around the country.  
 Thirty clinics that offer CAR-T treatments are selected at random from the CAR-T 
clinic locator on the Novartis website (Novartis AG, n.d.). The clinic list is included in 
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Appendix Table A.01. The annual demand of each clinic is calculated based on the total 
population of the state and the number of CAR-T treatment centers in that state. If there is 
no CAR-T center within a state, then the patients from that state are assumed to go to the 
closest out-of-state CAR-T facility for treatment. For a decentralized manufacturing 
network, the clinics are divided into clusters using the k-means clustering method (Likas, 
Vlassis, & J. Verbeek, 2003). The regional hub model divides the treatment centers into 2 
clusters corresponding to each manufacturing facility, while the decentralized model 
divides the treatment centers into 10 clusters. Within each cluster, the location of the 
manufacturing facility is determined as the demand weighted geometric center for each 
cluster.  The locations of the manufacturing and treatment facilities calculated in the study 
are presented in Figure 3.9. The production capacity of the factory is determined to be the 









 The manufacturing cost from each manufacturing facility is determined using the 
cost modeling simulation based on the production facility. The study assumes no regional 
differences in cost value and disease incident rate. For the logistic cost, an average $2 per 
miles delivery cost based on ultra cold train truck delivery cost estimation is used for the 
calculation. The total distance traveled per batch is approximated by the round trip 
geometric distance between the treatment facility and manufacturing facility times a 
circuity factor of 1.2 for US road (Ballou, Rahardja, & Sakai, 2002). The logistic cost is 
the product of average per mile delivery cost and total distance traveled for the roundtrip 
delivery of the CAR-T product. It is assumed that each travel carries only one CAR-T 
product to minimize the vein-to-vein time for CAR-T treatment. 
 Based on the methodology described above, the network simulation model is 
constructed and executed to calculate the estimated COGS for the three manufacturing 
networks. Regional hub and centralized manufacturing have similar COGS, while the 
decentralized model has the highest COGS (Figure 3.10). The regional hub model has the 
lowest COGS at $80,271. The reduction in logistic cost for decentralized manufacturing is 





Figure 3.10 Cost comparison between three manufacturing networks 
 
3.5 Conclusions 
 This chapter has provided a brief review of cell therapy cost structure, investigated 
the source of variations for different cost estimation studies, described the framework for 
cost modeling in the simulation platform, presented a benchmark for autologous CAR-T 
cost, and provided three case studies on how the cost module can be used to provide 
decision support to lower cost. The platform is a great tool for cell therapy manufacturers 
to improve and develop the manufacturing facility and supply chain network. A detailed 
case study is presented in the next chapter to showcase how the simulation platform is used 








CHAPTER 4    COST-EFFECTIVE DESIGN OF AN ALLOGENEIC 
STEM CELL FACTORY FOR JOINT CARTILAGE DEFECT 
 
 In this chapter, the decision support system will be applied to design a commercial 
manufacturing facility for the production of a cell therapy product containing allogeneic 
human MSCs for the treatment of joint cartilage following the Quality by Design principle. 
The cell therapy product is a cartilage graft with 2 ml of biomaterial with 
2.5 × 106 cells/500 μL/cm2 . The commercial facility will need to follow all cGMP 
standards, and the final product will need to satisfy FDA requirements with a 10-year 
manufacturing horizon presented in this case study. 
4.1 Background 
Joint cartilage defect is a common ailment that affects approximately 900,000 
Americans annually, leading to more than 200,000 surgical procedures (Farr, Cole, 
Dhawan, Kercher, & Sherman, 2011; Merkely, Ackermann, & Lattermann, 2018). It is 
estimated that cartilage defects in 60-66% of knees undergo arthroscopy (Curl et al., 1997; 
Hjelle, Solheim, Strand, Muri, & Brittberg, 2002; Merkely et al., 2018). As joint cartilage 
has poor regenerative capacity and a very limited healing potential (Charalambous, 2014), 
it is very unlikely for damaged joint cartilage to recover its full structure, function, and 
mechanical properties and will gradually progress towards osteoarthritis (J A Buckwalter 
& Mankin, 1998; Hunziker, 2002). If left untreated, the joint can eventually become so 




Treatment for joint cartilage defect aims to control symptoms, restore joint 
functions and prevent long-term osteoarthritis (Detterline, Goldberg, Bach, & Cole, 2005; 
Doran & Young, 2013b). Current treatments include chondral debridement, a surgical 
procedure where the cartilage that hinders joint tissue is physically removed (Lysholm & 
Gillquist, 1982); marrow stimulation techniques, where a hole is drilled into the bone of 
the defect site so that the mesenchymal stem cell from bone marrow can bleed into and fill 
the defect site to restore cartilage (Kreuz et al., 2006); and whole-tissue transplantation, in 
which the defect tissue is excised and replaced with mature tissue from an autologous donor 
site or allogeneic tissue (Smith, Knutsen, & Richardson, 2005).  
 Another method in treating joint cartilage defects is using autologous chondrocyte 
implantation (ACI) to repair cartilage defects (Peterson, Minas, Brittberg, Lindahl, & 
Surgery, 2003). For this method, cartilage tissue is harvested surgically in a preliminary 
operation. The chondrocytes are then isolated from the harvested tissue and expanded in 
culture for 4-6 weeks. The expanded tissue is then injected into the cartilage defect through 
another surgery (Abelow, Guillen, & Ramos, 2006; Zhang et al., 2006). In 2016, the U.S. 
Food and Drug Administration (FDA) officially approved a new generation of ACI 
procedure called MACI (autologous cultured chondrocytes on porcine collagen membrane) 
for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients 
(US Food and Drug Administration, 2016). This is the first FDA-approved tissue-
engineered autologous cell product. In a recent clinical trial report, 88% had excellent or 
good results with MACI, a significantly higher percentage than other treatment options 
(Saris et al., 2014).  
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 Despite the numerous benefits provided by chondrocytes implantation, the 
procedure also came with many complications. As the process requests harvesting of donor 
cartilage tissue through surgery, the donor site has the possibility of becoming morbid. 
Also, in the case of patients with extensive cartilage degeneration, there may not be enough 
healthy chondrocyte population available for extraction. Lastly, during the ex vivo 
expansion process, chondrocytes have a high chance of becoming dedifferentiated and 
losing their therapeutic characteristics (Cournil-Henrionnet et al., 2008; Dell’Accio, De 
Bari, & Luyten, 2001; Stewart, Saunders, Burton-Wurster, & Macleod, 2000). Bone 
marrow-derived mesenchymal stem cells (BM-MSC) provide a good alternative option. 
The harvest of BM MSC does not require surgery; isolation and expansion of MSC are 
relatively easy. MSC can differentiate into chondrocytes and can be administered 
allogeneically.  
 BM-MSC are generally harvested through aspiration from a donor’s iliac crests 
under regional or general anesthesia (Centeno et al., 2008; Shapiro, Kazmerchak, Heckman, 
Zubair, & O’Connor, 2017). These cells are also made available in commercial stem cell 
banks such as PromoCell. In addition, due to low expression of HLA Class I and absence 
of HLA Class II antigen (Le Blanc, Tammik, Rosendahl, Zetterberg, & Ringdén, 2003), 
MSC can be administered to patients without HLA antigen matching and thus can be 
manufactured allogeneically, making large-scale manufacturing and distribution possible. 
Several ongoing clinical trials of use MSC directly for joint cartilage defect with some 
evidence of cartilage recovery (Goldberg, Mitchell, Soans, Kim, & Zaidi, 2017; Lee & 
Wang, 2017; Simaria et al., 2013). Furthermore, MSCs have the ability to differentiate into 
a variety of different cell lineages, including chondrocytes, under the proper differentiation 
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condition (Somoza, Welter, Correa, & Caplan, 2014). Therefore, it is advantageous to 
combine the benefit of ease of MSC manufacturing and the therapeutic properties of 
chondrocytes implant.  
The aim of this study is to design a commercial cell manufacturing facility that can deliver 
100,000 does of cartilage graft per year worldwide through allogeneic MSC expansion and 
differentiation into chondrocytes. The process will be carried out in an optimized cell 
expansion system through quality by design principles with required purification, 
validation, and logistic functions that follow cGMP regulations. The proposed facility will 
account for 12.4% of existing and predicted cartilage defects in all OECD countries. The 
proposed plan can guide future stem cell manufacturer who wishes to enter the new cell 
and gene therapy industry. 
4.2 Process flow diagram and material balance 
 The manufacturing process flow for the allogeneic MSC differentiated cartilage 
graft is detailed in Figure 4.1. Frozen MSC vials received from cell banks will first be 
stored in the on-site cell banking facilities. When the facility receives a production order, 
the vials will be thawed and plated on T75 flasks in a designated tissue culture room. After 
ten days, these cells will be enzymatically removed from the flask and seeded onto 
microcarriers within the 0.1L Vertical-Wheel Bioreactor maintained in incubators. These 
cells will be removed from the microcarriers and passaged into larger bioreactors every 
week, first to 0.5L bioreactor, then to 3L, 15L, and in the end 80L bioreactor. In the 80L 
bioreactor, expansion media will be switched to differentiation media to induce 
differentiation into chondrocytes. After differentiation, the cells will be enzymatically 
removed from the microcarrier and concentrated through a fluidized bed centrifuge. The 
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differentiated chondrocyte will be sorted from undifferentiated MSC using magnetic-
activated cell sorting (MACS). The lot will then be divided into vials with 2.5 × 107 
chondrocytes and filled using an automated filling machine. The vials will be frozen in a 
controlled rate fridge and stored in cryo and shipped to the clinic. The doctor will thaw the 
cells in the clinic, inject the cell suspension into the defect area and cover the suspension 
using a bilayer porcine collagen type I/III membrane during surgery. Expansion, 
differentiation, and formulation media are purchased from an outside supplier and stored 
in the media storage room, while phosphate-buffered saline (PBS) used in the process will 
be prepared in a media prep room prior to starting each batch. A more thorough acceptance 
quality control test and release test will be performed before expansion during the vial 
thawing stage and before release during the vial filling process. Sterility, viability, cell 
counts, surface marker, and karyotype will be tested at these stages. While simpler quality 
control tests such as cell count and viability test will be performed after each expansion 
stage during the manufacturing process. Material balance for cells and media for major unit 
operations on a per batch basis are shown in Table 4.1, and detailed material balance for 
major reagents in each stream are shown in Appendix Table A.02. In the table, streams for 
major unit operations are labeled in green, streams for fresh media injection are labeled in 
pink, streams for quality control are labeled in blue, and streams for waste treatment are 






Figure 4.1 Process flow diagram for MSC production 
 
Table 4.1 Material balances for cells and media in major unit operations per batch 
 







1 MSC Cell Thawing 2.50E+05 2.50E+05 \ 0.0025 0.5 
2 
MSC Expansion: T75 
Flask 2.50E+05 5.62E+05 0.0025 0.015 10 
3 
MSC Expansion: 0.1L 
Reactor 5.62E+05 3.63E+06 0.015 0.08 7 
4 
MSC Expansion: 0.5L 
Reactor 3.63E+06 1.56E+07 0.08 0.1 7 
5 
MSC Expansion: 3L 
Reactor 1.56E+07 1.01E+08 0.1 2 7 
6 
MSC Expansion 15L 
Reactor 1.01E+08 6.54E+08 2 10 7 
7 
MSC Differentiation: 80L 
Reactor 6.54E+08 1.58E+10 10 50 14 
8 Centrifugation 1.58E+10 1.55E+10 50 0.6 0.1 
9 Purification 1.55E+10 6.60E+09 0.6 2.5 0.15 
1





4.3 Process description 
4.3.1 Process design using Quality by Design (QbD) principles 
 All processes are designed and optimized using quality by design principles to 
ensure compliance with cGMP standards while maintaining manufacturing efficiency and 
cost-effectiveness. The Quality Target Product Profile (QTPP) for the products is 
determined first listed below in Table 4.2. The entire manufacturing process is designed to 
make cure MSC manufacturing process follows the QTPP attributes listed below. 
 
Table 4.2 QTPP attributes for MSC 
Property Criteria 
Identity 
CD105+ CD166+ CD45- CD73+ CD90+ CD80- HLA-
DR- (Cournil-Henrionnet et al., 2008) 
Viability >80% 
Potency 
Collagen type II+ Alcian Blue+ SOX9+ COL2A1+ 
(Bravery et al., 2013; Ridgway, 2012) 
Cell Expansion 
Up to Passage 9 (Capelli et al., 2015; Ullah, Hamouda, 
Stich, Sittinger, & Ringe, 2012) 
Doses 250,000 cells/µL/cm2 
Impurity 
Endotoxin, mycoplasma, bacteria, virus, particulates free 




37 oC for expansion, 32 oC for differentiation (King & 
Miller, 2007) 
CO2 level 5% (Fekete et al., 2012) 
Maximum Confluency 80% (Doran & Young, 2013a) 
Minimum Glucose 
Concentration 1 mM (Kim & Cho, 2013) 
pH level 7.22 




4.3.2 Overall process description 
4.3.2.1 Upstream processes 
 Various cell media and PBS solution will be prepared in a dedicated media 
preparation area. PBS will be prepared using a mixture of dry chemical consists of sodium 
chloride, potassium chloride, sodium phosphate, potassium phosphate, and water for 
injection (WFI) for a final pH of 7.22 using an established recipe for cGMP production 
(“Common stock solutions, buffers, and media,” 2001). RoosterNourishTM MSC media 
from RoosterBio® will be used for MSC expansion (Fekete et al., 2012), while 
MesenCultTM ACF Chondrogenic Differentiation Medium will be used for the 
chondrogenic differentiation of MSC (Solchaga, Penick, & Welter, 2011). These media are 
standardized, xeno-free, cGMP compliant with little batch-to-batch variation. 
4.3.2.2 Cell banking & vial thaw 
 MSC cells will be purchased from a cGMP-compliant commercial stem cell bank. 
Stem cell donors will underwent strict health history and infectious disease screening, 
required by the Food and Drug Administration, American Association of Blood Banks, and 
Foundation for the Accreditation of Cellular Therapy (Alsuhaibani et al., 2015; Tomblyn 
et al., 2009). As one batch of MSC can be made into 2,500 doses. It is critical that MSC 
donor is of optimal health and free of any infectious disease. After arriving at the 
manufacturing facility, cells will be stored in a VWR® CryoPro® Liquid Nitrogen Cell 
Storage Tank, which is capable of holding a maximum of 875 vials larger than 500 
vials/tank requirement.  The tank will be refilled with liquid nitrogen every two weeks.  
When a production order is received, a vial will be removed from the storage and thawed 
with Astero® Thawstar® CFT2 Cell Thawing System. The cell thawing system has a 
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cGMP compliant standardized thawing procedure that is reproducible and leads to higher 
cell recovery and less variability between batches.  
4.3.2.3 Cell expansion & differentiation 
 MSC from vials will be expanded from passage 4 to passage 9 in a series of 
bioreactor trains. 5% of the cells will be taken from the vial initially to check for its viability, 
sterility, and density. After passing the acceptance check, the MSC will be first expanded 
in the T75 vial flask for 10 days until reaching 80% confluency(Fekete et al., 2012; Lawson 
et al., 2017).  The MSC cells will be subsequently grown in PBS Mini 0.1, 0.5, 3, 15, 80 
with microcarriers for each cell passage at 37 oC and 5% CO2. There will be two full-
volume media exchanges during the cultural duration for T75 Flasks and two half-volume 
for each bioreactor. 
 For each scale-up process, the adherent MSC cells will be detached using a xeno-
free trypsinization reagent TrypLE™ following the standard detachment protocol from the 
reagent manufacturer. The cells will first be rinsed with PBS and incubated with the 
trypsinization reagent before switching out with growth media and transfer into a new 
bioreactor. After a week of expansion in the PBS Mini 80 reactor, the expansion media will 




Figure 4.2 MSC expansion and differentiation process 
 
4.3.2.4 Purification 
 The differentiated cells are first concentrated using the kSep centrifugation system 
to remove microcarrier, waste, extracellular matrix, and other cellular secretions. 
Chondrogenic differentiated MSC cells will then be sorted out from undifferentiated cells 
using magnetic-activated sorting techniques (MACS) by CliniMACS machine. The yields 
of the MACS process will be about 60%, with a processing time of three hours (Miltenyi, 
Müller, Weichel, & Radbruch, 1990). Compared to undifferentiated MSC cells, 
differentiated cells will have reduced expression of surface markers of CD44, CD73, CD90, 
CD105, and CD166 (Ullah et al., 2012). Chondrocytes can then be isolated through 
negative selection with the chondrocytes eluted in the media. The CliniMACS machine has 
been approved for use in the cGMP manufacturing process. 
4.3.2.5 Inactivation 
 Viral inactivation is a critical step in the traditional monoclonal antibody (mAb) 
biomanufacturing process to ensure product safety. Common viral inactivation techniques 
involve filtering, solvent/detergent treatment, low pH inactivation, heating, and 
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chromatography (Clutterbuck et al., 2017). However, since the final product is comprised 
of living cells, all these techniques would reduce cell viability and become unfeasible 
(Schnitzler et al., 2016). Strict quality control and monitoring system are implemented 
throughout the manufacturing process for virus detection. All reagents and starting material 
will require FDA approval for sterility (Giancola, Bonfini, & Iacone, 2012). As all the 
equipment used in the process are closed and fully automated, the manufacturing will take 
place in a Class C cleanroom with equipment placed in isolators to prevent contamination 
from surroundings (Lopes et al., 2018). WFI used for media preparation will also be 
purified according to cGMP protocol to remove all viruses. 
4.3.2.6 Preparation for shipping 
 Purified chondrocytes will be filled into individual cryovials using the standard 
procedure from the fill-it Vial Filling System from TAP Biosystem. The system can fill 96 
vials in less than one minute and can minimize exposure to DMSO and reduce variability 
between vials. 2.6 hours are required to fill up to 250 vials.  
 After vials are filled, the products will be put in a controlled-rate freezer to freeze 
the vial to recommended -120 oC for cell storage (Li & Ma, 2012). Vials will also be labeled 
using a designated barcode system that allows tracking throughout the entire process. 
4.3.2.7 Quality control test 
 Quality control tests will be performed based on strict  FDA regulations on human 
cells, tissues, or cellular and tissue-based products (HCT/Ps) (Food and Drug 
Administration, 2008; Food and Drug Admins-CBER, 2014). The quality tests required for 




Table 4.3 List of quality control tests 
Test Attribute Equipment 
Cell Density Particle Counter 
Viability Trypsin Blue 
Identity Flow Cytometer, qPCR 
Sterility Blood Culture Media Test 
Karyotype Karyotype Test Kit 
Mycoplasma  Plate Reader 
Endotoxin Endotoxin Test Kit 
Residual Virus qPCR 
Potency Alcian Blue and Type II Collagen Dye 
 
4.3.2.8 Acceptance check 
 Cells thawed from the cell bank will first go through an acceptance check to ensure 
the cells are up to standard for expansion. The cells will be checked for density, sterility, 
and identity. Flow cytometry will be used to check for the identity and purity of MSC cells 
according to the test criteria detailed in the previous section.  
4.3.2.9 In-process check 
 Samples from cells during the expansion stage will be taken out and tested for cell 
counts and identity using a multisizer and flow cytometer to monitor its growth and 
differentiation status. 
4.3.2.10 Release check 
 Before the cells are released, the product will undergo a list of sterility tests, 
including sterility culture, mycoplasma, endotoxin, and vesicular stomatitis virus (VSV-g) 
to ensure its safety (National Academies, 2017; Scott, Schachtele; Christine, Clouser; Joy, 
2013). The identity and potency of chondrocytes will also be checked from both its surface 
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cell marker using a flow cytometer as well as a more definitive qPCR test. Only the vials 
that pass all tests will be cryogenically stored and sent to the medical facility.  
4.3.2.11 Storage and shipment 
 The frozen vial will be kept in the CryoPort cryogenic storage system awaiting 
shipment orders. These cryogenic vials will be shipped by a specialized biologics shipper 
using SmartPAK II Condition System that allows real-time monitoring and tracking 
throughout the entire delivery process to ensure cells arrive at the clinics under the optimal 
condition. 
4.3.2.12 Supply chain 
 Stock levels of critical reagents are being monitored using the manufacturing 
modeling software designed for this facility. A periodic review product policy is 
implemented to minimize the chance of backorder and reduce the impact of a potential 
supply chain disruption scenario (Bossert & Willems, 2007). According to the simulation 
model, the current implementation of a weekly reordering schedule can successfully 






Figure 4.3 Inventory management for critical reagent using weekly periodic review 
 
4.3.2.13 Waste management 
 All consumables, including equipment components, used media, and other reagents, 
will be autoclaved before disposal. Media that are not yet disposed of will be temporarily 
stored in a stainless-steel waste tank before being autoclaved and disposed of into the sewer 
system. The autoclave process will be performed once a day. 
4.4 Energy balance and utility requirement 
 Energy and utility use calculation is performed using the processing modeling 
software developed for the manufacturing process based on a production capacity of 
100,000 items per year. Cost for electricity, gas and heat, sewer treatment, and water is 
based on industrial utility for the state of Pennsylvania, the site of the production facility 
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(Pennsylvania Scorecard, n.d.; Priddy, n.d.). The electricity usage is estimated from the 
equipment specification sheet and follows the calculation used for the industrial cost report 
analysis of two GMP Cell therapy product facilities, the Berlin-Brandenburg Center for 
Regenerative Therapies, Berlin, Germany, and the University of California Davis GMP 
facility in Sacramento, California, the United States (Abou-El-Enein et al., 2013) The total 
yearly cost for utilities is estimated to be about $66,093 which is around $0.66 for each 
treatment dose given the 100,000 dosages per year production capacity.    
 
 




Table 4.4 Total utility cost per year and per good based on 100,000 items/year 
 
Units (kWh) Cost/Unit (USD) Yearly Cost Cost per Good 
Electricity (kWh) 890479 0.0692  $ 61,621.15   $ 0.62  
Gas and heat (MMBTU) 284 13.98  $ 3,970.32   $ 0.04  
Sewer (1000 gallon) 73 5  $ 365.00   $ 0.00  
Water (1000 gallon) 67 2.04  $ 136.68   $ 0.00  
Total    $ 66,093.15   $ 0.66  
 
 
4.4.1 Equipment cost summary 
 The total purchased equipment cost is 1.72 Million USD for the first year, with the 
scale-up of operation each year. By year 4, the total equipment cost will reach 4.4 Million 
USD (Figure 4.5). A detailed list of all equipment used in the manufacturing facility can 
be found in Appendix Table A.03. Equipment for major unit operations such as cell culture, 
purification, and isolation accounts for 70% of the equipment cost. The price is consistent 
with the cost analysis research conducted on other similar cell therapy factories by Lopes 
et al., in which they calculated the equipment cost of their cell therapy factory at 2.45 
Million USD to produce 260 batches a year (Lopes et al., 2018). While the factory at year 






Figure 4.5 Total equipment purchase cost breakdown by category for each year 
 
4.4.2 Fixed capital investment summary 
 Using the estimation method outlined in the Bioprocess textbook (Petrides, 2013), 
shown in Table 4.5, the fixed capital cost can be estimated by adding total plant direct cost, 
total plant indirect cost, with a multiplier for contractor’s fee and contingency. As cell 
therapy product manufacturing is a nascent industry with very strict federal regulation and 
oversight, the highest multiplier is used to estimate the fixed capital cost.  As shown in 





Table 4.5 Fixed capital cost estimation heuristic adapted from “Bioprocess Design and 
Economics” (Petrides, 2013) 
 
 
Table 4.6 Breakdown of capital cost 
Equipment Purchase Cost  $                            4,405,303  
Total Plant Direct Cost  $                          31,497,916  
Total Plant Indirect Cost  $                          22,048,542  
Total Plant Cost  $                          53,546,458  
Total Fixed Capital  $                          61,578,427  
 
 
4.5 Analytical approach, product safety, and efficacy 
 The QTPP of the final product and the list of quality control items have been 
addressed in the above sections. All the specifications will be satisfied to ensure the safety 
and efficacy of the products. The testing procedure can be categorized into starting material, 
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intermediate and final product test (Fekete et al., 2012), as shown in Figure 4.6. In the 
beginning, the sterility and impurity of source human cells/tissues and other process 
consumables will be tested. Also, cytokine analysis will be performed to quantify human 
cytokines and chemokines. During and after cell cultivation, the CO2, pH, glucose, and 
oxygen level will be real-time monitored. For each three to four days, the supernatant 
samples will be collected for sterility, impurity, and cytokines monitoring. After cultivation 
and purification, the cell sample will be collected to perform all the basic testing mention 
above; in addition, the cell density, karyotype, and potency will be verified to ensure all 
the designed CQA specifications are fulfilled. Finally, the final product will be 
cryopreserved and shipped to the patient when needed. A basic sterility and impurity test 
will be performed right before the treatment. 
 
 




4.5.1 Manufacturing safety 
 The manufacturing process safety includes two major aspects, staff and 
environment. The process steps will be performed by qualified personnel. According to the 
Code of Federal Regulation (CFR) (U.S. Food and Drug Administration, 2020a), all 
personnel must be clear about the potential hazards of their work, and they must be well 
trained to have enough knowledge and capability to perform their assignment safely. In 
addition, for each process step, standard operating procedures (SOP) will be established 
and updated to reduce the risk of exposing contaminated human cells or tissue to staff or 
the environment. These SOPs will be accessible to all related personnel (U.S. Food and 
Drug Administration, 2020b). 
 Incoming reagents, bio-materials, and process consumables will be sterilized and 
verified to meet CGTP specifications (U.S. Food and Drug Administration, 2020e). Upon 
arrival, in-house sterilization and test procedure will be performed to ensure the safety of 
staff and product. While processing human cells or tissues, each material should be clearly 
labeled and must not be mixed. For every reagent or process material, the date of receipt, 
quantity, purpose, storage, usage, date of expiration, and the material test result will be 
recorded and properly stored for at least 3 years.  
 The equipment chose in the manufacturing process is compliant with cGMP 
regulation and certified by FDA. According to CFR (U.S. Food and Drug Administration, 
2020d), the construction, electronics, mechanical, and operation mechanism should be well 
designed to prevent disease or contaminated material exposure to staff and workplace. 
During operation, each piece of equipment will be regularly monitored, calibrated, and 
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maintained to prevent unexpected problems. All the equipment condition and maintenance 
records will be documented and retained for 3 years.   
 During the manufacturing process, the environmental condition of the working 
space will be real-time monitored to ensure all equipment and process are operating under 
appropriate conditions, thus preventing unexpected contamination or exposure of 
communicable disease agents (U.S. Food and Drug Administration, 2020c). Typical 
environmental conditions include temperature, humidity, pressure, ventilation, and air 
filtration. The sensor and monitoring system will be checked repeatedly. 
4.6 Economic analysis 
4.6.1 Manufacturing cost 
 Manufacturing costs include materials (cells, media, reagents), consumables (bags, 
tubes, flasks, bottles, …), labor (operators, supervisors, quality), capital depreciation 
(facility and equipment), distribution, and utility (electricity, waste, maintenance). Labor 
consists of operations with 3 personnel per clean room, including 2 operators and 1 
supervisor and 3 quality with 2 quality control and 1 quality assurance (Lopes et al., 2018). 
A 10% failure rate is assumed per batch. The cost breakdown is shown in Figure 4.7. The 
first-year cost is estimated at $136 million and ramped up to $277 million to year 4. Cost 
per batch starts at $110 thousand and comes down to $70 thousand as manufacturing 
gradually scaled up. Since one batch can produce 250 doses in the model, the cost per dose 
is only $542 at the beginning and came down to $276 by year 4 (Table 4.7). This cost is 
currently lower than the cost of many other allogeneic cell therapy products from literature 
since the cell dosage required for this treatment (~25 million cells) are much lower than 
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other MSC products (~100 million cells). (Abbasalizadeh, Pakzad, Cabral, & Baharvand, 
2017; Hassan et al., 2015; M. J. Jenkins & Farid, 2018). The reduced cell dosage can lower 
treatment cost considerably, and the calculated cost per batch is consistent with estimations 




Figure 4.7 Pie chart of cost breakdown for year 4–10 
 
Table 4.7 Manufacturing cost per year, per batch, and per dose 
 
 Year 1   Year 2   Year 3   Year 4-10  
Yearly Cost  $13,559,728   $15,907,836   $25,346,063   $27,651,258  
Cost per Batch  $112,998   $72,308   $ 81,761   $70,901  




4.6.2 Financial analysis 
 To account for expenses in R & D as well as sales and marketing expenses, the 
selling price is determined so that COGS account for 15% of the total sale. The 15% target 
is determined based on the industrial standard for biologic manufacturing and allogenic 
cell therapy manufacturing (M. J. Jenkins & Farid, 2018). For autologous cell therapy, 
COGS usually account for a much larger percentage of the total sale (Lipsitz et al., 2017; 
Spink & Steinsapir, 2018). Based on a COGS of $276 per dose, the drug is set to be $1,840 
per treatment. The MACI treatment price for joint cartilage damage is $14,083. The unit 
cost of mosaicplasty is $2,639, and the unit cost of microfracture is $1,405. This price is 
85% cheaper than the best treatment available, and this treatment has a much shorter and 
easier recovery period compared to microfracture, which usually requires the patient to be 
on crutches for four to six weeks after the surgery (Steadman et al., 2003). Given the size 
of the market, the selling price will generate annual revenue of $46 M in year 1 and rises 
to $184 M in year 4. This will result in a gross profit of $32.5 M in year 1 and rises to 
$156.4 M in year 4. The investment in building the factory will be paid back within 2 years. 
However, R & D, clinical trial, and other operating costs, including administrative and 
sales & marketing cost, are not included, and these items also represent significant capital 
investment and operating costs that are not captured from this analysis. 
4.7 Conclusions and recommendations 
 This case study demonstrated how the simulation framework can examine and 
compare different process configurations and choose a process design that delivers a 
quality product with commercial viability. The case study has demonstrated the robustness 
of the design by examining the project from various angles and has performed both 
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economic and technical reviews from analyzing the technical and market aspects of 
existing products. The report includes analysis on equipment selection, material balance, 
facility design, economic feasibility, as well as compliance with regulatory requirements, 
including quality control methods and facility layout. The proposed process incorporates 
various design options that meet the overall goal of designing an ethically sound, high 
quality, and commercially competitive product.  
 In order to truly realize the proposed commercial process, further validation of the 
simulation result will need to be validated. Hosts of thorough and comprehensive 
experiments and assays need to be conducted to evaluate the effectiveness of the product 
and verify the optimized equipment setup described in the case study. Investors and 
developers should also monitor closely any recent development in biotechnology and 
manufacturing science to evaluate and incorporate new technologies to improve the current 
design or update the timeline and cost of the facilities according to more recent scientific 





CHAPTER 5    RISK ANALYSIS AND MITIGATION FOR CELL 
THERAPY INDUSTRY – A CASE STUDY 
 
5.1 Background 
 COVID-19 pandemic has wreaked great havoc on the pharmaceutical industry. 
Trade restrictions (U.S. Senate Republican Policy Committee 2020) and sudden surges in 
demand for many medical supplies used to treat COVID-19 or manufacture vaccines have 
led to a worldwide shortage of pharmaceuticals, critical raw materials, reagents, and other 
medical supplies (Shih, 2020). Travel restrictions and social distancing measures have also 
created staffing shortages for many pharmaceutical manufacturing plants and healthcare 
facilities. As of October 2020, 43% of acute care medicines such as antibiotics, blood 
thinners, and sedatives are in short supply (Silverman, 2020). These shortages have 
continuously worsened as the rate of new COVID-19 cases kept climbing throughout the 
initial year of the pandemic (Schondelmeyer et al., 2020). Within the pharmaceutical 
industry as a whole, cell therapy manufacturing institutions and companies are facing 
especially severe disruptions due to their complex manufacturing supply chains. Border 
closures and travel bans have prevented patients' cells from reaching manufacturing 
facilities. Some products that would have been delivered fresh have had to be 
cryopreserved. Hospitals have pushed back cell therapy treatments and clinical trials to 
reserve ICU spaces for COVID-19 patients (Boodman, 2020). Production capacities for 
many contract manufacturing facilities have also been affected due to their commitments 
to vaccines and ancillary reagent manufacturing for COVID-19 (Stanton, 2020). Many 
skilled operators within these facilities have also been recruited and diverted for vaccine 
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and reagent manufacturing, causing further shortages within the cell therapy industry (Koh, 
2021). A recent McKinsey & Company survey has shown that one-third of cell therapy 
companies reported manufacturing delays or complete shutdowns, and one in five reported 
problems with the procurement of supplies (Loche, Mossmann, Van der Veken, & Yang, 
2020).  
 Cell therapy is a fast-growing emerging industry with great potential for treating 
fatal and life-debilitating ailments, including cancer, genetic, and neurodegenerative 
diseases, that can often lead to remarkable clinical outcomes. An example of a more recent 
cell therapy product, CARTITUDE-1, from Janssen and Legend Biotech, reported a 95% 
remission rate for clinical trial participants with relapsed or refractory multiple myeloma 
(Madduri et al., 2020). As of February 2021, 19 cell therapy products have been approved 
by the US FDA, according to the official agency website (U.S. Food and Drug 
Administration, 2021). By 2025, it is estimated that 10–20 cell therapy products will be 
approved every year (Gottlieb & Marks, 2019). However, the use of live cells and tissues 
has also created additional challenges and vulnerabilities for the manufacturing and 
logistics of cell therapy compared to other pharmaceutical products.  
 The manufacturing process begins by collecting immune cells from the patient or a 
donor at a collection facility. The cells are then transported to a manufacturing facility for 
processing. Following manufacturing, quality control testing, and quality assurance review, 
the final drug product is transported to the treatment facility, where it is administered to 
the patient (Figure 5.1). The entire process includes numerous hand-off points where the 
chain of custody must be maintained. The complexities of donor sourcing and transport 
live cells, reagents, consumables, and other medical supplies between manufacturing and 
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administration share many similarities with organ and tissue transplantation. The large-
scale standardized pharmaceutical manufacturing process combined with a supply chain as 
complex as that of organ transplantation makes managing the cell therapy manufacturing 
and supply chain uniquely challenging compared to traditional pharmaceutical 
manufacturing. 
           
 
Figure 5.1 Illustration of a typical autologous cell therapy supply chain depicting the 
journey of the cell therapy product                                                                                                                                                                                                                                                                                                                                                                                                     
 
The cell therapy industry is a new and relatively small player in the 
biopharmaceutical industry as a whole. Most manufacturers rely on sole suppliers for 
highly specialized critical reagents, making the manufacturers vulnerable to any supply 
chain disruption (Wang et al., 2019). The supply chain is even more vulnerable for 
autologous cell therapy manufacturers, where a patient's own cells are collected as the raw 
material for the patient's cell therapy product. During the first peak of the COVID-19 
pandemic in spring 2020, many blood collection centers either completely stopped 
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operations or severely reduced their operating time to protect the health of the blood donors 
and to divert many of the healthcare workers who collect blood to fight the pandemic 
(Boodman, 2020). The availability of manufacturing and quality testing personnel has also 
been affected similarly. Stay-at-home orders, social distancing measures, infections and 
the quarantine of staff members, lack of personal protective equipment (PPE), diversion of 
key personnel to manufacture COVID-19 related therapeutics and vaccines, and now the 
administration of vaccines have all contributed to staff shortages (Koh, 2021; Loche et al., 
2020). These procurement and staffing challenges have led to delays or halts in the cell 
therapy manufacturing process during the spring 2020 peak. Even though many of the 
manufacturing facilities and collection centers recovered to varying extents from the initial 
shock, there are still many lingering disruption impacts with each subsequent wave. The 
system remains vulnerable to the resurgence of COVID-19 variants or the emergence of a 
new infectious agent in the future. A list of potential sources of supply chain disruptions 
for the cell therapy industry is presented in Table 5.1. Many cell therapy products are used 
on critical patients with limited prognoses, and the products themselves are living cells that 
can deteriorate over time if not properly stored or cryopreserved. A delay in manufacturing 
and a rejection of a final drug product for administration will leave patients with 





Table 5.1 Sources of risks and disruptions in cell therapy manufacturing 
Supplier Side Manufacturing Side Hospital Side 
Shipping delays and halts Lack of PPE Lack of ICU beds 
Border closures; canceled 
flights for donors 
Social distancing and 
quarantine of essential  
personnel 
Shortage of drug supply to 
treat side effects 
Shortage of reagents Delays in service and repair 
of equipment 
Travel restrictions for 
patients 
Failure of regulatory 
inspections 
Failure of regulatory 
inspections 
Lack of hospital staff 
 
 
There are many “resilience” strategies that cell therapy companies can explore to 
reduce the risk of supply chain disruption and mitigate their impact (Table 5.2). Companies 
can prepare for such eventualities before a disruption occurs by cross-training staff that can 
substitute unavailable key manufacturing personnel and additional buffer stock for reagents. 
Companies can also seek additional suppliers for critical reagents and transship orders from 
other facilities in different geographical locations less impacted or not impacted by the 
disruption. After the disruption has started, companies can also explore different priority 






Table 5.2 The common types of resilience and mitigation strategies and the relative cost 
associated with implementing these policies 
Mitigate Impact 
(low implementation cost) 
Increase Preparedness 
(medium implementation cost) 
Build Resilience 
(high implementation cost) 
Priority 
Queueing/Rationing: 
Develop criteria for rationing 
Prioritize urgent care cases 
 
Scenario Planning: 
Simulate what-if scenarios 












Develop emergency protocols 
Have a clear chain of command 
Build Flexibility: 
Multi-skilled operators 
Reagent transshipment  
 
 
An agent-based computational simulation model can be a useful tool to help 
understand the effect of such disruptions on supply chain operations and patient access. 
Such a model can also be used as a decision support tool to determine the best resilience 
strategies for cell therapy manufacturers to minimize the impact of such disruptions. A 
simulation model can provide an information-rich view in a user-friendly interface for cell 
therapy manufacturers and other relevant stakeholders to intuitively plan different 
disruption scenarios customized to the precise configuration of their manufacturing facility. 
A simulation model can also capture many of the complex interactions between patients, 
cell specimens, reagents, operators, and equipment that traditional mathematical modeling 








For the research presented here, the agent-based simulation model described in 
Chapter 2 is customized for risk analysis and mitigation for studying the impact of 
disruptions on the cell therapy industry. In particular, this chapter examines the impact of 
prolonged reductions in the availability of reagents and operators caused by the COVID-
19 pandemic on manufacturing performance and patient access. The chapter also 
investigates how incorporating redundancy into production and reagent inventory while 
implementing a priority policy for the sickest patients during the disruption can help 
mitigate the negative impact of such disruptions. The effectiveness of the patient priority 
policy is also compared to that of the typical first-come, first-serve scheduling rule. Using 
the information from these simulations, mitigation strategies applicable to cell therapy 
manufacturers can be proposed and prioritized to prepare for COVID-19 and other future 
pandemics and disruption events.  
5.2 Methods 
 Using the agent-based simulation model developed and described in Chapter 2 
(Wang et al., 2019), this study investigates how a reduction in operator and reagent 
availability can impact the patients' adverse outcome rate, suggesting a method to reduce 
the impact of the disruption. Reagent availability is defined as the amount of reagent supply 
available to order from the supplier weekly. Operator availability is defined as the number 
of operators directly involved with the production process available in one shift. Both the 
reagent and operator availability are measured against a perfectly lean manufacturing setup 
with zero redundancy.  
 For the reagents, this study implements a periodic-review base-stock inventory 
policy. For this policy, an order for reagent replenishment is placed every week to bring 
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the inventory position up to the base stock level S. It is assumed that an order will take a 
week to arrive at the facility. The base stock level is the sum of the average demand µ 
during the review period D and delivery period L, and the standard deviation of demand σ 
multiplied by a safety factor k. The safety factor determines how likely the inventory will 
experience a stockout. A safety factor of 3 corresponds to a 0.03% chance of a stockout 
event, and a safety factor of 6 corresponds to a 3 in a million chance of having a stockout 
event. Thus, 
𝑆𝑆 = 𝜇𝜇𝐷𝐷+𝐿𝐿 + 𝑘𝑘𝜎𝜎𝐷𝐷+𝐿𝐿 
During the disruption, delivery capacity or the amount of reagent available to purchase 
from the supplier will be limited for each order. The factory will not be able to order up to 
the base stock level if the difference between the current inventory level and the base stock 
level is larger than the delivery capacity. Reagent availability measures the delivery 
capacity during the disruption. 100% reagent availability means the amount of reagent 
supply available to order from the supplier is equal to or greater than the average amount 
of reagent needed during the same period.  
For the operator, 100% operator availability means the number of available operators 
in a single shift is at least as great as the minimum number of full-time-equivalent (FTE) 
operators required in a shift based on labor hour calculation. The minimum number of 
operators is calculated by dividing the total labor hours required to meet demand over the 
time period by the number of working hours per operator. A facility with an annual 
production capacity of 5,000 batches will require an average of 520.5 labor hours to meet 
the average demand in a 12-hour shift, requiring at least 44 operators to cover. Thus, a 
factory with 50 operators in a shift corresponds to an operator availability of 50/44 = 
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113.6%. A list with the minimum number of operators required per shift is included in 
Table 5.3. 
 
Table 5.3 The minimum number of operators required per shift to fulfill production 
orders in a perfectly lean system based on labor hour calculation 






 In reality, a perfect lean system is unsustainable since having only the capacity to 
meet the average demand means the facility will be unable to meet the demand 50% of the 
time when the actual demand is larger than average. It is also improbable for an operator 
to schedule the production process with zero wait time or downtime in between orders. 
Therefore, all manufacturing facilities in a normal setting must operate with some 
redundancy above 100% availability to account for stochasticity and scheduling limitations. 
 The adverse outcome includes patient mortality during treatment or disease 
progression beyond the capability of the treatment. Lack of clinical staff or ICU beds 
during the pandemic peak can also contribute to the adverse outcome of a patient unable to 
get treated. The study set the length of the disruption to 6 months and 12 months with 
varying degrees of severity from a full disruption to a partial disruption to test whether the 
manufacturing facility can reach a new steady state in manufacturing capability under a 
prolonged disruption. Both the number of operators in a shift and the maximum number of 
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units of reagents allowed for purchase in one order are reduced during the disruption. The 
study also tested different disruption scenarios on manufacturing facilities of different sizes: 
an academic manufacturing facility capable of making 250 batches a year, a midsize 
factory making 1,500 batches a year, and a large factory making 5,000 batches a year.  
 To understand how redundancy affects the impact of disruption, the study varied 
baseline labor and utilization and base stock level to investigate how much manufacturing 
delay and the patient adverse outcome can be reduced by increasing the number of 
operators and reagent inventory during normal operations. A list of parameters and 
assumptions used in the simulation platform is shown in Table 5.4. 
 
Table 5.4 List of input parameters and assumptions used in the simulation model. 
Bioreactor numbers are in great excess to remove any impacts caused by potential 
bioreactor shortages 
Parameter Baseline Value Treatment in the Case Study 
Patient Daily Adverse Outcome Chance  0.3% Fixed 
Viability of Final Cell Products 80% Fixed 
Tissue Contamination Probability During Sampling 0.2% Fixed 
No. of Bioreactors 100 Fixed 
Bioreactor Failure Rate 1% Fixed 
Bioreactor Repair Time (day) 5 Fixed 
Reagent Delivery Frequency (day) 7 Fixed 
Delivery Lead Time 7 Fixed 
Patients per Year 250 | 1,500 | 5,000 Variated 
Base Stock Level Safety Factor 0 | 3 | 6 Variated 




 During normal operations, the manufacturing facility is assumed to have a first-in-
first-out policy (FIFO), where the order of the manufacturing requests is solely determined 
by the order arrival time. However, during the disruption where the manufacturing 
capability is limited, the study also investigated whether assigning urgent critical patients 
ahead of regular patients will improve the overall patient adverse outcome without 
potentially worsening the condition of regular patients. The order of all urgent patients' 
requests and regular patients' requests are serviced FIFO within each patient category. This 
admittance policy will be referred to as the priority queueing policy (PQ). A reduction in 
adverse outcome rate is calculated by comparing the difference in patient adverse outcome 
rate with a facility using the FIFO policy and the PQ policy under the same disruption 
parameters. The list of parameters used in the PQ study is listed in Table 5.5. 
 
Table 5.5 Parameters used for priority queueing policy study 
Regular Patient Daily Adverse Outcome 
Probability 
0.003 
Urgent Patient Daily Adverse Outcome 
Probability 
0.02 
Initial Proportion of Urgent Patient 0.1 
Probability of Regular Patient Become 




 Each 3-dimensional surface plot generated in the Results section was determined 
by varying both operator and reagent availability and generated with 10,000 simulation 
experiments. Each line in the 2-dimensional line plot in the Results section was determined 
by varying either operator or reagent availability to generate 5,000 experiments.  The 
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number of experiments was chosen to reduce the effect of the randomness of the stochastic 
simulation model. A list of definitions of terms used in the study is shown in Table 5.6. 
 
Table 5.6 A list of definitions for the terms used in this study 
Operator Availability Number of available operators in a shift over the minimum number 
of operators needed to cover the average demand of labor hour in a 
perfectly lean system 
Reagent Availability Amount of reagent available to purchase in an order over the 
average demand of reagent in a perfectly lean system 
Adverse Outcome 
Rate 
Number of deceased patients or patients who have progressed 
beyond the capability of the treatment during the manufacturing 
process over the total number of patients received 
Availability Threshold Adverse outcome rate starts to rise when operator/reagent 
availability drops below the availability threshold 
Base Stock Reagents are replenished up to the base stock amount during each 
procurement order 
Safety Factor A factor that determines the amount of safety stock to prepare for 
uncertainty in demand 
FIFO System A first-in-first-out system where patients orders are processed based 
on the order of arrivals 
PQ System Priority queueing system when the sickest patients are moved to the 




 This study analyzed how a sudden reduction in the available number of operators 
and a restriction in the amount of reagent supply available impacts the manufacturing 
process and how a delay in beginning therapy manufacturing can affect patient benefits. 
This simulation study assumes the manufacturing process is only initiated when there is 
sufficient reagent supply, available operators, and other equipment and resources to carry 
the process from beginning to finish. There will be no delay or stoppage during the 
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manufacturing process once the process begins unless the patient becomes too sick to 
receive the treatment or deceased.  
 Based on the simulation experiments, an “s-curve” behavior is observed for patient 
adverse outcome rate as operator and reagent availability decreased, where patient adverse 
outcome rate is defined as the ratio of the number of people who either become too sick to 
receive the treatment or who passed away during the production. The patient adverse 
outcome rate stays relatively flat when operator and reagent availability starts to drop. After 
these availabilities are lowered to a certain threshold, the adverse outcome rate starts to 
increase rapidly and slows down as the availability drops close to 0. The longer the 
disruption lasts, the worse patient adverse outcome becomes (Figure 5.3).  
 
 
Figure 5.3 Response surface plots of patient adverse outcome rate versus reagent and 
operator availability for different disruption duration: 6 months (left) and 12 months 
(right) for a large factory with 5,000 orders per year 
 
5.3.1 Operator disruption 
 To understand the impact of operator availability on patient adverse outcome rate, 
the study simulated scenarios where the number of operators was reduced during the 
disruption while the reagent supply remained adequate. As shown in Figure 5.4, the patient 
105 
 
adverse outcome rate starts to rise once operator availability drops below approximately 
115%, above the theoretically minimum number of operators required. As the factory 
receives orders at random times, it is impossible for the operators to perfectly schedule unit 
operations that fill up 100% of their shift without gaps in between. Having the theoretically 
minimum number of operators per shift will cause production delay and an increase in 
adverse outcome rate. The availability threshold above which adverse outcome starts to 
rise appears to be consistent for factories of different sizes and disruption durations. A 12-
month long disruption can more than double the adverse outcome rate to 0.21 from a 6-
month disruption of 0.11. Larger factories seem to have a slightly worse increase in adverse 
outcomes compared to smaller factories. As the small factory (250 annual capacity) only 
requires a minimum of 4 people for 100% operator availability, it is not included in the 





Figure 5.4 Impact of reduced operator availability during a disruption of different lengths 
on adverse outcomes on factories of different sizes. 100% operator availability is the 
minimum number of people required to cover the average labor hour demand in a shift 
 
5.3.2 Reagent supply disruption 
 The study has investigated how different base stock levels, disruption durations, 
and different production capacities can impact patient adverse outcome rates when reagent 
supply becomes limited during the disruption period. When the disruption occurs, factories 
will have an upper limit on how much reagent they can order at a single decision epoch 
(e.g., once a week) and may no longer be able to order up to the base stock level. The safety 
factor, annual production capacities, and durations of disruption are listed in Table 5.7. The 
reagent availability threshold above which patient adverse outcome rate starts to rise are 
listed in Table 5.7 as well. The reduced delivery limit determines reagent availability 
107 
 
during the disruption over the average reagent demand during the same period. Unlike 
operator availability, the patient adverse outcome rate does not start to rise until reagent 
availability drops below 50% for all scenarios studied. The asymmetry arises because 
reagents can be stored while labor cannot. Factories will continue to receive new reagents 
at a reduced capacity, yet they will not be able to find replacements for absent operators 
during the disruption period. 
 
Table 5.7 Reagent availability threshold for factories of different production capacities, 
of different safety factors for the base stock position, and the duration of disruptions 
6 months 12 months 
  Safety Factor 
 
Annual Capacity 0 3 6  0 3 6 
250 45.6% 45.6% 45.6% 250 45.6% 45.6% 45.6% 
1,500 39.1% 39.1% 39.1% 1,500 39.1% 36.9% 41.3% 
5,000 37.8% 37.8% 37.8% 5,000 39.1% 38.5% 38.5% 
 
 
 Similar to operator availability, a longer period of disruption leads to a higher 
patient adverse outcome rate (Figure 5.5). A year-long disruption can lead to a 19% patient 
adverse outcome rate, while a half-year-long disruption leads to a 7% patient adverse 
outcome rate. A lower safety factor for the base stock position will lead to a very small 
increase in patient adverse outcome rate (Figure 5.5a), although the safety factor does not 
appear to affect the availability threshold. On the other hand, larger factories have a lower 
availability threshold and can withstand a larger supply disruption without affecting the 
patient adverse outcome rate (Figure 5.5b). Larger factories have a lower adverse outcome 
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rate at a moderate level of disruption but will fare slightly worse than smaller factories 
when reagent availability becomes too low. 
 
 
Figure 5.5 Patient adverse outcome rate vs. reagent availability with a) different base 
stock safety factor and disruption duration for a 5,000 annual capacity factory; b) 
different annual capacity and disruption duration for a base stock position with a safety 
factor of 6. 100% reagent availability means reagent delivery capacity equals the average 
demand of reagent in a perfectly lean system 
 
5.3.3 Priority queueing policy 
 Implementing a priority queueing (PQ) policy has a modest effect in reducing the 
patient adverse outcome rate when operator availability is low, but the effect is almost 
negligible for reagent disruption (Figure 5.6a). The priority queueing policy has the largest 
impact at a moderate level of personnel disruption, reducing the patient adverse outcome 
rate by 7% when operators are reduced to 60% availability (Figure 5.6b). This policy is 
less effective at a higher disruption level since all the orders are backed up due to a lack of 
production personnel. 
 Further analysis also indicates that PQ reduces overall adverse outcomes without 
negatively impact on other patients waiting for their therapies. The PQ policy sharply 
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decreases the patient adverse outcome rate for urgent patients by almost 24% during 
moderate operator disruption without negatively impacting the patient adverse outcome 
rate for other patients ( Figure 5.6c, d). 
 
 
Figure 5.6 Impact of priority queueing policy on the patient adverse outcome. a) Overall 
adverse outcome reduction by priority policy. b) Adverse outcome reduction vs. operator 
availability. c) Regular patient adverse outcome reduction by PQ. d) urgent patient 
outcome reduction by PQ  
 
5.4 Discussion 
 Simulation platforms can be effective tools for cell therapy manufacturers and cell 
processing facilities to conduct scenario planning, testing resilience, and making 
contingency plans for potential disruption events such as the COVID-19 pandemic. Having 
a simulation model of the actual manufacturing facility is especially helpful for complex 
and expensive manufacturing and supply chain system to estimate potential impacts 
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without the oversimplifications necessary for a pure analytical model to be tractable. 
However, foundational results derived from analytical models can be useful.  For example, 
the simulation model described is much more computationally efficient. The reagent 
replenishment policy is assumed to be a base stock inventory policy, a policy known to be 
optimal for such inventory control problems, given a carefully chosen base stock level. The 
inputs to the model were based on published clinical trial data and communications with 
cell therapy manufacturers (Neelapu et al., 2017; Schuster et al., 2019). Manufacturers and 
cell processing facilities handling different cell types and with different facility 
configurations may obtain results that vary from those presented above using the 
simulation platform. The current model does not consider the cost-effectiveness of building 
redundancies into the manufacturing system and assumes the reagent and operator 
shortages remain constant during the length of the disruption. Future model development 
will incorporate cost information to understand the trade-offs between the cost of goods 
and system resilience to reach a setup that balances cost and risk. A decision support tool 
can also be developed to advise manufacturers on the optimal facility configuration to 
respond to the changing level of disruption severity in real-time.  
 Based on the simulation findings, cell therapy manufacturers should prioritize 
protecting key manufacturing personnel during the pandemic. Missing a few operators can 
significantly raise the patient adverse outcome rate. Hence, the facility manager should 
ensure that operators follow strict social distancing and other transmission prevention 
protocols as well as secure a sufficient supply of personal protective equipment (PPE) 
during the COVID-19 pandemic and future epidemics from emerging infectious diseases.  
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 Facility managers should also be assured that a small amount of reagent supply 
reduction may only have a negligible impact on patients' benefit if facilities can still receive 
the limited supply on schedule. Establishing a second reagent supplier is also critical to 
maintaining the necessary manufacturing performance. In a hypothetical situation with two 
reagent suppliers, each supplying 50% of the reagent, a shutdown of one supplier will still 
allow the factory to have a reagent availability of 50%, above the ~40% threshold 
discovered in this study. In this scenario, having a second supplier will allow the factory to 
supply treatment to the patients without increasing the patient adverse outcome rate.   
 Larger factories appear to fare better than smaller factories faced with reagent 
disruption, but slightly worse with personnel shortage. A possible explanation is that 
smaller factories can be more efficient in reassigning the remaining workforce to cover the 
shift from absent operators, while larger factories have a larger safety stock compared to 
smaller factories to withstand a reagent shortage. It is also suspected that the impact of 
personnel shortage can also be influenced by the level of cross-training among the 
manufacturing personnel, which is not currently modeled in the simulation since smaller 
facilities are less likely to have reserves of people trained in specialized skills. These results 
may have further implications in understanding whether large, centralized manufacturing 
is more resilient than a network of smaller decentralized manufacturing facilities. The 
simulation model can be further utilized to study how a decentralized network of 
manufacturing facilities can be used to build overall system resilience and provide insight 
into facility design and space allocation for inventory areas. 
 The study has shown that priority queueing policies have the potential to 
significantly reduce the overall patient adverse outcome rate without negatively affecting 
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the patient adverse outcome rate of any subgroup of patients. The platform therefore can 
be a useful tool for manufacturers as well as policymakers, clinicians, and bioethicists to 
establish the criteria and conditions for priority access that maximize overall patient benefit. 
The simulation platform can be further developed to build a dynamic priority policy where 
the criteria for priority access or rationing can be automatically modified based on the 
availability of resources and severity of disruption in real-time. Such a tool would not only 
be beneficial to cell therapy developers but also for allocating vaccines, medicines in short 
supply, and ICU beds to manage COVID-19 and future pandemics from emerging 
infectious disease. 
 The utility of using a simulation tool to develop resilience in a manufacturing 
network will go beyond the COVID-19 pandemic. Even more than traditional 
pharmaceutical manufacturers, cell therapy developers will need to re-examine their 
inventory, equipment, and personnel policies and reorient the manufacturing and supply 
chain strategy from just-in-time and lean manufacture to a more robust and resilient 
approach that will save lives and reduce cost during serious disruptions. 
5.5 Conclusions 
 This chapter has demonstrated the usefulness of an agent-based simulation platform 
to understand and develop resilience and risk mitigation strategies for cell therapy 
manufacturers. The study has shown that factories can tolerate reagent shortages better than 
labor shortages before the patient adverse outcome rate increases significantly.  Consistent 
with intuition, longer disruptions are more difficult for factories to withstand and exact 
heavier tolls on patient benefit than shorter disruptions. The model suggests that 
manufacturing facilities with larger production capacities and a larger reagent safety stock 
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seems to have better patient outcomes during reagent shortages, while facilities with 
smaller production capacities tend to have better patient outcomes during labor shortages. 
Priority queueing policies can be effective in reducing the overall patient adverse outcome 
rate for a moderate level of operator disruption but has a negligible benefit for a severe 
level of operator disruption and appears to have no added benefit for reagent disruption. 
 Further studies can be conducted to analyze and develop resilience strategies for a 
network of manufacturing facilities and compare the resilience capability between 
centralized and decentralized manufacturing systems. A real-time decision support tool can 
also be developed to help manufacturers adjust operations in real-time to mitigate the 




CHAPTER 6    CONCLUSIONS AND SUGGESTED FUTURE 
WORKS 
 
6.1 Technological and fundamental knowledge contributions 
 This thesis describes a simulation-based decision support platform to help cell 
therapy manufacturers, including cell, gene, and tissue-engineered products, improve 
production and distribution. The platform can simulate a single or multi-network of 
manufacturing facilities throughout a large region. The platform incorporates a customized 
manufacturing process as each product is customized per patient and treats patients as part 
of the supply chain process before and after production. It takes into account reagent supply, 
temporal and individual variations of cell properties, demand surges, shortages of 
biological API, delivery location and timeframe, and other parameters for the 
manufacturing and supply chain process. The platform enables manufacturers to devise 
system-level decisions to improve facility design and predicts “what if” scenarios to plan 
for unexpected disruptions through the simulation of thousands of potential scenarios that 
may occur within the manufacturing and distribution of the cell therapy product. The 
simulations help manufacturers identify problems early on and throughout the overall 
manufacturing and supply chain, and could lead to reduced costs, improved yield, quality, 
and speed for the regenerative medicine products. Simulation case studies of different cell 
types (CAR-T, MSC, and iPSC) and different cell sources (autologous and allogeneic) are 
developed and presented. The thesis described multiple case studies that help stakeholders 
inform decision-making in cost reduction, automation, logistics, inventory management, 
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risk management, and scheduling with the possibility of adding more functions based on 
customers’ demand.  
 In particular, Chapter 1 and Chapter 2 described why the agent-based simulation 
platform could be particularly suited to tackle fundamental challenges in cell therapy 
manufacturing and supply chain and described in detail the features and functionalities of 
the agent-based simulation platform. The chapters also outlined and listed the detailed 
manufacturing and supply chain requirement for different cell therapy products. 
 Chapter 3 and Chapter 4 described the development and application of a cell 
therapy cost model that is capable of estimating and reducing manufacturing and 
distribution costs, as well as providing a platform for cost-effective facility design. The 
model enabled manufacturers to evaluate and choose appropriate technologies, reagents, 
equipment for the production process as well as compare different factory configurations 
to reduce manufacturing costs and improve yield. The model can also be extended to a 
network level to enable manufacturers to compare different distribution network strategies 
that minimize operating costs.  
 On a fundamental knowledge level, the thesis used the platform to identify all cost 
items within the cell therapy supply chain and established a methodology to categorize and 
analyze the cost based on transparency and variation among companies. A realistic 
manufacturing cost range was also established that serves as a benchmark for 
manufacturers to identify areas of cost reduction, and a list of potential cost reduction 
strategies for different cost categories was also provided. 
 Chapter 5 described the development of a scenario planning tool based on the 
simulation platform that can forecast the impact of supply chain disruption on 
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manufacturing facilities and analyzed the impact of different risk mitigation strategies. The 
platform can also provide decision support to determine the appropriate amount of 
resources needed to recover from supplier disruption and minimize the impact on patients. 
 On a fundamental knowledge level, the thesis used the platform to discover that 
patient adverse outcome displays an “s-curve” behavior with resource availability during 
disruption events, and impact to patients can be minimized if resource availability is kept 
above a certain threshold. The thesis established that a perfectly lean factory with no 
redundancy would not be able to recover from a disruption event, and having multiple 
suppliers can greatly reduce manufacturing delays. Additionally, implementing a priority 
queueing policy for urgent patients effectively reduces overall patient adverse outcome for 
reagent disruptions without negatively impacting regular patient outcome. 
6.2 Current limitations and plan for further technology improvements 
 The technology described in the thesis is currently a NASA Technology Readiness 
Level (TRL) 4 prototype. The prototype has been tested and validated by academic and 
industrial collaborators within the NSF Engineering Research Center for Cell 
Manufacturing Technologies partnership. The technology has not yet been validated by a 
broad range of users or in an industrial environment for specific applications.  More case 
studies and tests are still needed in a real-life environment to improve the functionality and 
optimize the design of the platform before the platform is ready for deployment in real 
industry settings. Some of the next steps to take for improving the platform include: 
• Develop additional models for a wide range of regenerative medicine products 
beyond cell therapy to expand the broad applicability of the platform 
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• Generate support tools that help guide the manufacturer through various decision-
making processes within the supply and manufacturing chain 
• Refine the platform with an easy-to-use graphical user interface that can be 
widely deployed and interfaced with existing in-house database systems 
• Test the platform within a real-world manufacturing facility to demonstrate that 
the system can provide meaningful and valuable insight to users of the technology 
• Present the technology and supportive data to companies developing cell therapy 
products or those contract organizations specializing in manufacturing and 
distribution 
6.3 Potential future research directions 
 This thesis will end with discussions of potential future directions of cell therapy 
manufacturing and propositions of future research topics. 
6.3.1 Personalized manufacturing process for personalized cell therapy 
 Personalized medicine adapts medical decisions, practices, interventions, and 
products to the individual patient based on the patient’s predicted response or risk of 
disease. The current simulation platform can be adapted to analyze the use and value of 
real-time patient and therapy data for personalized cell therapy manufacturing to enable 
new bio-manufacturing capabilities that do not exist today. The proposed research can 
address new modeling, analytic, and computational challenges to determine how to 
manufacture a cell therapy by adjusting the manufacturing and quality control processes in 
real-time, based on the current state of the patient’s health and the current state of the 
therapy-in-process, in order to maximize clinical outcome at the time of therapy transfusion. 
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These results then set the stage to determine: (i) the order of patients waiting for therapy 
manufacturing to begin, based on current patient data for these patients, to maximize 
average clinical outcome at the time of therapy transfusion without reducing the clinical 
outcome of any patient in the wait queue and (ii) the best level of manufacturing capacity 
and the best reagent replenishment policy at a single manufacturing facility, given real-
time patient and therapy data for all patients with therapies-in-progress, in order to 
minimize capital bioreactor expenditure and reagent replenishment costs for a given patient 
service level. The facility-level results set the stage for understanding the impact of supplier 
disruptions and the need for supply chain resilience at a time when the industry is moving 
from clinical trials to commercialization.   
6.3.2 AI-based decision support for patient-centric manufacturing 
 The cell therapy manufacturing process involves multiple stakeholders with 
different emphasis on key performance indicators as listed in Table 2.1. Insurers may 
prioritize lowering cell therapy price and cost, while healthcare providers tend to 
emphasize the timeliness and efficacy of the product. By integrating machine learning 
algorithms into the simulation platforms, policymakers can explore and evaluate a set of 
reward and penalty policies that encourage the stakeholders, including manufacturers, 
payers, and care providers, to think from the patient’s perspective and prioritize patient 
outcome over other metrics.  
 The machine learning algorithms developed for the simulation platform will then 
be able to assist and automate many of the cell therapy manufacturing and supply chain 
decision-making process. For example, a reinforcement learning (RL) based job dispatcher 
algorithm can assign and schedule patients' orders to different manufacturing facilities and 
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automatically adapt to the complex and changing dynamics of the cell therapy supply chain. 
The RL-based dispatcher system has the potential to significantly improve the fulfillment 
rate and reduce delays over the intuition-based manual job dispatching process. 
6.3.3 Intelligent cell therapy manufacturing with bio-cyber-physical system 
 The high manufacturing failure rate and difficulties to hit label specifications have 
driven many companies to deploy Industry 4.0 technologies to improve their processes. 
The current simulation platform can integrate with Industry 4.0 sensors, AI-driven real-
time data analytics, and advanced process control capabilities to turn the manufacturing 
facility into a bio-cyber-physical system (BCPS) that fully integrates the physical agents 
within the facility with the virtual agents in the simulation platform. The computational 
core of the integrated system starts with an AI scenario learner that focuses on learning 
manufacturing patterns through a pattern recognition neural network. The recognized 
pattern will then be passed on to an AI system designer that uses generative network 
algorithms to continuously update the parameters within the virtual-physical integrated 
agents that leads to an improved production process. This integrated system will enable 
real-time predictions of final product quality at all manufacturing stages and create a more 
agile manufacturing process that automatically adapts to the manufacturing environment 
at any given time.  
 One particular application that is of great importance to the manufacturers is to use 
the system for preventative maintenance. Critical equipment in the facility can be equipped 
with connected and smart sensors that are connected to the platform. The platform will then 
be able to analyze equipment performances, predict the likelihood of equipment failures 
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and order preventative maintenance before the machines break down, reducing downtime 







Table A.01 List of CAR-T facilities used in Chapter 3 Case Study 3. 
Name City 
Banner University of Arizona Medical Center/HCTT Program Tucson, AZ 
Phoenix Children’s Hospital Phoenix, AZ 
UCSD Moores Cancer Center La Jolla, CA 
Lucile Packard Children’s Hospital Stanford Palo Alto, CA 
Yale Cancer Center New Haven, CT 
Christiana Care Health Services, Inc Newark, DE 
Johns Hopkins All Children’s Hospital St. Petersburg, FL 
Winship Cancer Institute of Emory University Atlanta, GA 
University of Chicago Medicine Chicago, IL 
Rush University Medical Center Chicago, IL 
 Loyola University Medical Center Maywood, IL 
Holden Comprehensive Cancer Center at The University of 
Iowa 
Iowa City, IA 
The University of Kansas Cancer Center Westwood, KS 
University of Maryland Marlene and Stewart Greenebaum 
Comprehensive Cancer Center 
Baltimore MD 
Dana-Farber Boston Children’s Cancer & Blood Disorders 
Center 
Boston, MA 
Beth Israel Deaconess Medical Center Boston, MA 
Barbara Ann Karmanos Cancer Institute Detroit, MI 
The Children’s Mercy Hospital Kansas City, MO 
Roswell Park Comprehensive Cancer Center Buffalo, NY 
NewYork-Presbyterian / Columbia University Irving Medical 
Center 
New York, NY 
Cincinnati Children’s Hospital Medical Center Cincinnati, OH 
University Hospitals Rainbow Babies & Children’s Cleveland, OH 
Penn State Children’s Hospital Hershey, PA 
Penn Medicine Abramson Cancer Center, Cell Therapy & 
Transplant Program 
Philadelphia, PA 
Fox Chase-Temple University Hospital Bone Marrow 
Transplant Program 
Philadelphia, PA 
Sarah Cannon Center for Blood Cancer at Tri Star Centennial Nashville, TN 
Texas Children’s Hospital Houston, TX 
Children’s Medical Center Dallas Dallas, TX 
Texas Transplant Institute at Methodist Hospital San Antonio, TX 






Table A.02 Detailed material balances for reagents per batch in Chapter 4 



















Cold Bank T75 Flasks                   
T75 Flasks 
0.1L 




Reactor 0.12                 
0.5L 
Reactor 3L Reactor 0.4                 
3L Reactor 
15L 




Reactor 10                 
80L 
Reactor Centrifuge     5   7.853         
Centrifuge MACS     0.3             
MACS Vial Fill     1.31       0.28     
Media 








Reactor 1.725         11.52       
Media 








Reactor 1757.15 100 5     1009.28       
Media 
Prep Centrifuge     2.8             
Media 





Prep               2.5 25 
PBS 
Buffer 
Prep T75 Flasks       0.015           
PBS 
Buffer 
Prep Centrifuge       25           
Trypsin 








Reactor         0.044         
Trypsin 








Reactor         7.853         
Cold Bank 
Quality 
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T75 Flasks 
Quality 

















Control   0.005               
Centrifuge 
Quality 
Control   0.005               
MACS 
Quality 
Control   0.005               
T75 Flasks 
Waste 








Treatment 1.49       0.044 11.52       
3L Reactor 
Waste 








Treatment 1757.15 100     7.853 1009.28       
Centrifuge 
Waste 
Treatment     7.5             
MACS 
Waste 
Treatment     0.004       0.001     
 
 
   
   
 




Table A.03 List of equipment used in the allogeneic stem cell factory in Chapter 4, 
1/2/3/4 in the unit column indicates the number of unit for year 1/2/3/4 and beyond 
Vendor Name Unit Description 
VWR Liquid nitrogen tank 2 Stores MSC seed vial 
Astero Cell thawing system 4 Thaw cells 
Thermo 
Fisher 
CO2 incubators 6 Supply CO2 and maintain temperature 
PBS MINI 0.1 Reactor 1/2/3/4 cell expansion 
PBS MINI 0.5 Reactor 1/2/3/4 cell expansion 
PBS MINI 3 Reactor 1/2/3/4 cell expansion 
PBS MINI 15 Reactor 1/2/3/4 cell expansion 
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